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Abstract 
 
 
Compound libraries of pharmaceutical companies include many novel compounds. In the 
optimization of biological activity and other drug properties, efficient approaches are needed. The 
n-in-one strategy in drug discovery was introduced 20 years ago. In this strategy, multiple samples 
are mixed or pooled prior to measurement or analysis. This allows the most promising compounds 
to be rapidly identified and then analysed. Although it is not a new approach, several new reviews 
of n-in-one pharmacokinetics have recently been published. Knowledge of cocktail dosing, sample 
pooling and other analytical methods has increased, and it is relevant to understand the role of n-in-
one in drug development. Study plans and proper analytical methods are important for n-in-one, as 
with any new drug discovery technologies that are introduced. According to recent publications, n-
in-one without proper method planning and validation has several risks, compound-compound 
interactions being the most serious. 
 
This thesis describes current and past n-in-one methods and presents three early experimental 
studies using mass spectrometry and the triple quadrupole instrument, on the application of n-in-one 
in drug discovery. In the first study, the fragmentation patterns of ten nitrophenoxy benzoate 
compounds were characterised and the presence of the compounds was determined in a 
combinatorial library. The influence of one or two nitro substituents and the alkyl chain length of 
methyl to pentyl on collision-induced fragmentation was studied, and interesting structure- 
fragmentation relationships were detected. Two nitro group compounds increased fragmentation 
compared to one nitro group, whereas less fragmentation was noted in molecules with a longer alkyl 
chain. The most abundant product ions were nitrophenoxy ions, which were also tested in the 
precursor ion screening of the combinatorial library. In the second study, the immobilized artificial 
membrane chromatographic method was transferred from ultraviolet detection to mass 
spectrometric analysis and a new method was developed. Mass spectra were scanned and the 
chromatographic retention of compounds was analysed using extract ion chromatograms. 
Comparisons were made between two different buffers as the mobile phase, between single 
compound analysis and n-in-one of nine compounds, and fast lipophilicity screening with gradient 
elution was also used. In the final study, a new method was developed for the quantitation of ten 
compounds in Caco-2 samples using liquid chromatography tandem mass spectrometry. 
Compounds were separated by liquid chromatography and quantified by selected reaction 
monitoring using mass spectrometry. This method was used in evaluation of n-in-one in Caco-2 
samples. 
 
Better understanding of n-in-one is needed in order to apply the strategy appropriately. These 
studies provided good examples of how methods for mixture analysis and mass spectrometry can be 
developed and tested for compound identification, method transfer and quantitation. In these new 
methods, several scanning modes of the triple quadrupole instrument are exemplified. The high 
sensitivity and selectivity that can be achieved using liquid chromatography mass spectrometry are 
especially important for new analytical methods using n-in-one. 
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List of original publications 
 
This licentiate thesis is based on the following three original publications, which will be referred to 
in the text by A, B and C: 
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nitrophenoxy) and alkyl 3-hydroxy-5-(2’,4’-dinitrophenoxy) benzoates, Rapid Commun. 
Mass Spectrom. 1999, 13, 1680-1684  
 
B. H. Kangas, T. Kotiaho, T. Salminen and R. Kostiainen, N-in-one determination of retention 
factors for drugs by immobilized artificial membrane chromatography coupled to 
atmospheric pressure chemical ionization mass spectrometry, Rapid Commun. Mass 
Spectrom. 2001, 15, 1501-1505  
 
C. L. Laitinen, H. Kangas, A.M. Kaukonen, K. Hakala, T. Kotiaho, R. Kostiainen, J. Hirvonen, 
N-in-One Permeability studies of heterogeneous sets of compounds across Caco-2 cell 
monolayers, Pharmaceutical Research 2003, 20 (2), 187-197 
 
 
The author has been the responsible scientist in the analytical studies of presented publications. In 
publications A and B she was also the main author. The compounds in publication A were 
synthesised by Robert Franzen and Jan Tois, who also performed NMR measurements on the 
compounds and measured the yields of the synthesis. The Ab initio calculations for publication A 
were offered by Jyrki Taskinen. 
 
In publication C, the author had a smaller role. She developed the final analytical method and 
analysed the first part of the samples. In addition, the author trained researcher Kati Hakala during 
the analysis and the final part of the study was then analysed by Kati Hakala. Furthermore, 
publication C was mainly written by Leena Laitinen, who was the responsible scientist in the 
permeability studies, the Caco-2 cell tests and the interpretation of the cell results using n-in-one. 
Therefore, the Caco-2 tests are only discussed in literature survey. 
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ABBREVIATIONS 
 
λmax absorption maximum e.g. in ultraviolet spectra 
 
ADME pharmacokinetic parameters of a drug: absorption, distribution, metabolism and 
excretion 
 
AUC area under the curve of a concentration versus time plot 
APCI atmospheric pressure chemical ionization 
APPI atmospheric pressure photo-ionisation 
CAD charged aerosol detection  
CID collision-induced dissociation 
CYP cytochrome P450 enzymes 
CLND chemiluminescent nitrogen detection  
ESI electrospray ionization 
ELSD evaporative light scattering detection 
FIA flow injection analysis 
Caco-2 human colon adrenocarcinoma cell line  
HBSS Hank’s balanced salt solution (an isotonic solution of inorganic salts present in 
approximately the correct physiological concentrations) 
HSA human serum albumin 
%HIA human intestinal absorption values  
IAM immobilised artificial membrane 
LC liquid chromatography 
LLOQ lower limit of quantitation 
Log D logarithm of the partition coefficient between an organic solvent and an aqueous phase 
(representative of both ionized and neutral forms in a given pH) 
 
Log P logarithm of the partition coefficient between an organic solvent and an aqueous phase 
(lipophilicity of the neutral form of a molecule) 
 
cLog P computerized estimation of Log P 
 
[M+H]+ protonated molecule 
[M-H]-  deprotonated molecule 
MDCK Mardin-Darby canine kidney cells 
MDR1 multidrug resistance drug transporter, p-glycoprotein  
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MS mass spectrometry / mass spectrometer 
MS/MS tandem mass spectrometry 
m/z mass-to-charge ratio 
MUX multiplexed electrospray interface 
Mw molecular weight 
NMR nuclear magnetic resonance 
PAMPA parallel artificial membrane permeability assay 
pKa the negative logarithm of a dissociation constant for acids, Ka (used for acid-base 
properties) 
SRM selected reaction monitoring 
TOF time of flight 
RSD relative standard deviation 
UGT UDP-glucuronosyl transferase enzymes 
UPLC ultra pressure liquid chromatography 
UV ultraviolet 
QSAR quantitative structure activity relationship 
QqQ triple quadrupole instrument 
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1. Introduction 
 
Drug discovery aims to identify compounds having the greatest potential as early as possible. N-in-
one is a methodology whereby this process is accelerated by using mixtures. The definition of n-in-
one includes studies that mix or pool compounds before measurement or analysis. The planning of 
such studies requires more effort than single compound studies, and the analysis of n-in-one 
samples also requires better methods than usual. This thesis presents new analytical methods for 
early drug discovery and n-in-one. The main focus was to develop mass spectrometric methods for 
combinatorial libraries, lipophilicity and absorption screening. These methods should differentiate 
and quantify the analytes in the presence of other components in the sample. The lack of specificity 
in previous analytical procedures was compensated by mass spectrometric analysis. The studies 
were conducted using a triple quadrupole mass spectrometric instrument. One qualitative study was 
carried out on a component of a combinatorial chemistry series. In addition, a lipophilicity 
screening method and quantitative method for absorption screening were tested using a set of 
molecules consisting of commercial small organic drugs. This thesis includes three separate studies, 
all presenting new mass spectrometric methods. The suitability of these analytical methods for n-in-
one applications was tested. New applications such as these can improve the efficacy and speed of 
early drug research. 
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2. Literature review 
 
 
2.1  Drug discovery of compounds and early screening 
 
2.1.1 Drug discovery of compounds and early tests 
 
New compounds for drug discovery are sought from natural sources or chemical synthesis (Edwards, 
P.J. et al., 2006, Newman, D.J. et al., 2003). Natural sources include, for example, microbiological 
fermentations, plant extractions or animal toxins. In chemical synthesis, various methods, such as 
combinatorial chemistry and microwaves, are used. Microwaves provide a catalyst for the reactions 
(Kappe, O.C. and Dallinger, D., 2003). Combinatorial chemistry is the methodology where compounds 
are prepared using a primary core structure (linker molecule) and selections of additional building 
blocks. It uses different reactions and several building blocks to increase the size of compounds. 
The number of compounds, N, can be calculated using N = bcd, where b, c and d are building 
blocks in each reaction vessel (Gallop, M.A. et al., 1994). 
 
Drug developers know that money can be saved if unpromising candidates are removed from 
compound selection at an early stage (Posner, B.A., 2005, Venkatesh, S. and Lipper, R. A., 2000, DiMasi 
J.A., 2002). It is estimated that the major reasons for clinical failures in 2000 were the lack of 
efficacy (30% of failures), clinical safety (30%), animal safety (30%) and pharmacokinetics and 
bioavailability reasons (10%) (Chackalamannil, S. and Desai, M., 2007). Pharmacokinetic and 
bioavailability problems have decline over the years, because scientists have encouraged the testing 
of solubility, dissolution, absorption (lipophilicity), transporters or metabolism to improve 
pharmacokinetics (Yu, H. and Adedoyin, A., 2003). Better understanding and multiple absorption, 
distribution, metabolism and elimination (ADME) tests in the drug development process explain the 
improved success rates. 
 
The permeability of compounds across cell membranes is important for drug absorption. Most drug 
candidates have passive transcellular transport as the main absorption mechanism, although not all. 
A relatively recent review by Shah (Shah, P., 2006) listed the drug absorption routes and mechanisms 
as follows: 1) passive transcellular route, 2) passive paracellular route, 3) carrier mediated transport, 
4) carrier mediated efflux and 5) vesicular transport. Lipophilic compounds are mainly transported 
via the transcellular pathway. Hydrophilic drugs (Mw < 200) and peptides partition poorly into cell 
membranes and are therefore transported via the paracellular pathway. Apart from passive 
diffusion, transporter proteins and carriers are involved in drug absorption. Some compounds enter 
the intestinal lumen using carriers (apical efflux) to limit intestinal absorption, and some 
macromolecular drugs are absorbed via vesicular transport. 
 
Nowadays, as confirmed by several researchers, absorption, distribution, metabolism and 
elimination (ADME) properties are characterised earlier and in parallel with pharmacological 
efficacy (Bedersford, A.P. et al., 2002, Chu, I. and Nomeir, A.A., 2006, Feng, W.Y., 2004, Stahl, M. et al., 
2006, Yu, H. and Adedoyin, A., 2003). Di and Kerns presented the optimization of drug properties as 
illustrated in Figure 1 (Di, L. and Kerns, E. H., 2003). In the figure, some common in vitro tests are 
listed, such as permeability, physiochemical and metabolism tests. The main physiochemical tests 
are to determine acid-base properties and lipid/water solubility. The lipid solubility, as the 
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logarithm of the partition coefficient between an organic solvent and an aqueous phase (Log P), is 
important for drug permeability. The acid-base properties of compounds, which influence their 
solubility, are usually expressed as the negative logarithm of a dissociation constant (pKa). For 
example, basic compounds become ionic in acidic solutions; furthermore, ions are usually more 
water soluble. Therefore, permeability varies for acidic or basic compounds at different pH values. 
 
In vivo pharmacokinetic tests, usually animal tests in early phases, are also mentioned in the same 
figure. During in vivo experiments, more of the investigated substance is needed, especially for 
larger laboratory animals. Usually, at the beginning of drug discovery, only a small quantity of the 
compound to be tested is available and rapid in vitro methods are preferred. The ADME tests are 
numerous and are not thoroughly reviewed here. Nevertheless, the following methods for 
lipophilicity and absorption screening are briefly presented: the partition coefficient (Log P), 
immobilised artificial membrane (IAM) chromatography and the parallel artificial membrane 
permeability assay (PAMPA), as well as human colon adrenocarcinoma (Caco-2) and Mardin-
Darby canine kidney (MDCK) cell assays. However, not all varieties of reverse phase 
chromatography and capillary electrophoresis methods (Henchoz, Y. et al, 2009) are discussed. 
 
 
 
 
Figure 1. Optimization in drug development using a parallel approach presented by Di, L. and 
Kerns, E. H., 2003: the absorption, distribution, metabolism and elimination (ADME) of a 
compound are measured in parallel with activity screening. 
 
 
2.1.2 In silico tests for lipophilicity and absorption 
 
Physiochemical values have been presented for optimizing the lipophilicity and absorption 
properties of drug candidates. Some of the physiochemical properties of a compound can directly be 
estimated from the compound structure or calculated by using computers, usually presented 
as in silico methods.   Poor absorption is apparent with candidates having more than 5 hydrogen 
bond donors, 10 hydrogen bond acceptors, a molecular weight in excess of 500 daltons, and log P 
above +5, known as Lipinski’s “Rule of 5” (Lipinski, C.A., et al., 1997). A slightly wider range for 
lipophilicity is given by Ghose, where the probability of succeeding is expressed to be one order of 
magnitude higher if log P is between -0.4 and 5.6 (Ghose, A.K. et al., 1999). The molecular surface 
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area values have also been used to predict oral drug absorption (Bergström, C. et al., 2003). Passive 
diffusion is sometimes expressed as a combination of lipophilicity, polar surface area, molecular 
volume, flexibility and hydrogen bonding (Balimane, P.V. et al., 2006). Some of 
the in silico studies as mentioned in review of Dickins and Waterbeemd (Dickins, M. and van 
de Waterbeemd, H., 2004) work closely with in vitro methods. These cannot all be all presented here, 
but a combinationing of some of the data sets is presented a little further. 
 
2.1.3 In vitro tests for lipophilicity and absorption 
 
The partition coefficient (Log P), immobilised artificial membrane (IAM) chromatography and 
parallel artificial membrane permeability assay (PAMPA) are commonly used in vitro tests for 
passive transcellular transport. Human colon adrenocarcinoma (Caco-2) and Mardin-Darby canine 
kidney (MDCK) cell assays are usually used if more information on permeability is needed, such as 
passive paracellular routes or active carrier mediated transport mechanisms. Table 1 presents a list 
of common in vitro lipophilicity and permeability tests. The list of lipophilic phases starts from the 
shake flask method to determine the octanol/water partition coefficient, which still remains the 
reference method for lipophilicity. The following tests are simplifications of the lipid bilayer of a 
cell membrane, and finally at the end are listed methods that use the monolayers of cell cultures. As 
the complexity of the lipid material increases, more information on permeability and drug 
absorption can also be expected. 
 
Table 1. Lipophilic phases used in the partition coefficient (Log P), immobilised artificial 
membrane (IAM) chromatography and parallel artificial membrane permeability assay (PAMPA), 
human colon adrenocarcinoma (Caco-2) and Mardin-Darby canine kidney (MDCK) cell assays for 
lipophilicity and absorption screening. 
 
In vitro test Lipophilic phase Ref. 
Log P octanol  
IAM silica as solid support 
+ phosphatidyl choline (PC) 
+ with of without glycerol linkers 
(Barbato, F. 
et al., 2004) 
PAMPA hydrophobic filter support 
+ mixture of (egg-) lecithin 
+ an inert organic solvent (1,7-octadiene or n-octanol) 
(Praveen V. 
et al., 2006) 
bio-mimetic 
PAMPA 
hydrophobic filter / porous chemical filter support 
+ lipid composition (PS, PI, PC, PE and CHO, springomyelin) 
+ an inert organic solvent (1,7, octadiene / n-octanol) 
+ additional pumps giving sink conditions 
(Kiyohiko S. 
et al., 2003, 
Corti, G. et al., 
2006) 
Caco-2 cell monolayer 
+ P-Glycoprotein transporters involved 
(Praveen, V. 
et al., 2006) 
MDCK cell monolayer 
+ leakier paracellular pathways 
+ might have transfected efflux transporters 
(Shah, P. 
et al., 2006) 
 
L-α-phosphatidylserine (PS), L-α-phosphatidylinositol (PI), L-α-phosphatidylcholine (PC), L-α-
phosphatidylethalamine (PE), cholesterol (CHO) 
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The typical reference parameter for lipophilicity is expressed as a logarithm of the partition 
coefficient between an organic solvent and an aqueous phase (Log P). The traditional organic 
solvent is n-octanol. Log P represents the lipophilicity of the neutral form of a molecule, while Log 
D is representative of both ionized and neutral forms at a given pH. Log P and Log D values are 
experimentally determined using an in vitro shake flask method. Since measurements of 
concentrations are laborious, theoretical Log P methods (cLogP) are often used for lipophilicity 
values. 
 
Immobilized artificial membrane (IAM and PAMPA) technologies use an immobilized lipid phase 
instead of octanol and physiological buffers instead of water. In an immobilised artificial membrane 
(IAM) chromatography column, the immobilized phospholipids mimic the cell membranes and the 
retention time correlates with the lipophilicity. Figure 2 presents the basis of the IAM model. 
Several columns with different phases have been developed and tested. Even though there is some 
variability in the retention factors of different phases, IAM chromatography columns might give as 
good as or more representative estimations of drug behaviour than the Log P value. 
 
In a computational study for predicting the volume of distribution, two chromatographic sets were 
combined (Hollosy, F. et al., 2006). The retention of immobilized artificial membrane (IAM) 
chromatography, as a marker for membrane binding in tissues, and the retention of human serum 
albumin (HSA) chromatography, as a marker for plasma protein binding, were tested against in vivo 
pharmacokinetic results. The calculations based on IAM results gave better estimations of the 
human volume of distribution than using computational values of log P (cLog P). Yet another test 
for predicting drug bioavailability was carried out by combining IAM results with in vitro hepatic 
metabolic clearance (Shin, B. et al., 2009). Users have also reported that the IAM method is simpler 
and faster compared to traditional Log P measurements (Pehourcq, F. et al., 2003). In addition, the 
IAM method might also be easily automated and possible impurities of the compounds will not 
affect the results (Hollosy, F. et al., 2006). 
 
 
 
 
 
 
 
Figure 2. Production of immobilized artificial membrane (IAM) columns, as presented by Regis 
Technologies: phosphatidyl choline chains are bound to the solid silica structure of the 
chromatographic column, mimicking the membrane structure 
(http://www.registech.com/InfoPages/IamInfo/IAMAbstracts.html). 
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Immobilised artificial membrane (IAM) data are used as an approximation of oral absorption, 
usually in combination with in silico parameters. Without in silico data the IAM results give only a 
moderate correlation compared with Caco-2 results (Stewardt, B.H. and Chan, H.O., 1998) or with 
human intestinal absorption values (Yen, T.E. et al., 2005). In penetration studies on the blood-brain 
barrier the IAM method has shown a slightly better correlation. For example, a good correlation for 
steroids and biogenic amines was achieved between IAM data and in vivo blood-brain data (Reichel, 
A. and Begley, D., 1998). Another test of IAM and blood-brain ratios gave a modest correlation, 
because cationic compounds were outliers (Salminen T. et al., 1997). 
 
The parallel artificial membrane permeability assay (PAMPA) measures the passive diffusion of 
compounds using filter support, the phospholipids of egg lecitin and an inert organic solvent such as 
1,7-octadiene or n-octanol (Praveen, V. et al., 2006). The PAMPA screening method has increased in 
popularity because of the possibility to simultaneously analyse multiple samples using high 
throughput well plates. The rather simple model has a variation known as bio-mimetic PAMPA, 
which also uses phospholipids materials such as IAM in the lipophilic phase (Sugano, K. et al., 2003). 
Currently, other filter materials and lipid compositions are also being evaluated. In addition, an 
unstirred water layer on the membrane has been shown to influence the resistance to drug 
permeation (Loftsson, T. et al., 2006). Stirring of the test mixture gives a dynamic construction when 
sink conditions are needed (Corti, G. et al., 2006). 
 
Human colon adrenocarcinoma (Caco-2) permeability tests use living cells that are isolated and 
introduced on a filter membrane, and after a growing period the cells compose a monolayer 
structure (Figure 3). First the compound is introduced in a buffer to the apical side of the filter. 
After incubation, the amount of compound that has passed across the cell monolayer is usually 
determined from the buffer solutions on the basolateral side. This absorption method is especially 
informative for passive absorption pathways, but also for transcellular transport mechanisms (Shah, 
P. et al., 2006, Artursson, P. et al., 2001, Hämäläinen, M.D. et al., 2004). Artursson’s research group 
noted in their 2001 review that the Caco-2 monolayer is ideal in identifying the potential absorption 
problems of small organic drugs (Artursson, P., et al., 2001). To reduce some quantitative differences 
in paracellular drug permeation between caco-2 and intestinal absorption in vivo, other cell culture 
models with leakier paracellular pathways have also been employed, such as Mardin-Darby canine 
kidney (MDCK) cells (Shah, P. et al., 2006). The review article of Shah also pointed out that the cell 
cultures of Caco-2 cells need a longer culture time: the passage time is 21 days for Caco-2 but only 
3-5 days for MDCK cells. Nevertheless, using an extended experimental time, the results of Caco-2 
can be qualitatively used for paracellular permeation. 
 
In cell monolayer tests (e.g. Caco-2), different transporters or metabolising enzymes might be 
involved (Shah, P. et al., 2006, Artursson, P. et al., 2001). The Caco-2 model, for example, sometimes 
has the capability to show the effects of P-glycoprotein transporters (multidrug resistance drug 
transporter, MDR1) and some metabolising enzymes such as UGT (UDP-glucuronosyl transferase 
enzymes). In addition, cells in the monolayer tests can be transfected with P-glycoprotein and other 
specific efflux transporters to allow a focus on active transport mechanisms. However, each 
metabolising enzyme (Thompson, T., 2001, Masimirembwa, C., et al., 2003) and transporter (Zhang, L., 
et al, 2006) has its own specialised tests, in which activity or binding are thoroughly assessed. 
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Figure 3. Caco-2 monolayer structure. Compounds are usually added to apical side of the cell 
monolayer and samples are collected from the basolateral side for permeability analysis. 
 
2.1.4 In silico with in vitro 
 
Several researchers have claimed that the combination of in vitro and in silico data provides a 
valuable drug discovery tool (Nasal, A. et al.., 2002, Matysiak, J., 2007, Yen, T.E. et al., 2005). For 
example, theoretical Log P (cLog P) values can be achieved more rapidly compared to in vitro 
methods. For improved decision making by medicinal chemists, the theoretical values need some 
updating with experimental data. However, few studies have presented the combination of in vitro 
and in silico data. In one study, the retention factor of an immobilized α1-acidglycoprotein (AGP) 
column for antihistamine drugs was measured in analysing the drug binding site of a protein 
(Kaliszan, R. et al., 1996), and in another, solute descriptors enhanced by immobilised artificial 
membrane (IAM) data have been calculated using the quantitative structure activity relationship 
(QSAR) (Sprunger, L et al., 2007). The limitation of QSAR analysis may be the size and quality of in 
vitro data available. 
 
The combination of in silico with in vitro immobilised artificial membrane (IAM) data is beneficial. 
Stewards and Chan investigated HIV drug candidates using both IAM and Caco-2 cell permeability 
tests (Stewardt, B.H. and Chan, H.O., 1998). IAM correlation with Caco-2 permeability improved if 
calculated molecular weight and hydrogen bonding values were added (r2 increased from 0.39 to 
0.91). Yen and co-workers have also tested human intestinal absorption values and IAM (Yen, T.E. 
et al., 2005). When the IAM data were combined with molecular descriptors, the correlation 
improved (R improved from 0.64 to 0.83). This may show that not only lipophilicity explains oral 
absorption. 
 
Immobilised artificial membrane (IAM) measurements have also been linked with in vitro activity 
tests using quantitative structure activity relationship (QSAR) analysis. In these studies, activity and 
IAM lipophilicity correlations were calculated for active anti-inflammatory drugs and antitumor 
drug candidates. Comparison of a small set of anti-inflammatory drugs and cyclooxygenase-2 
enzyme inhibition gave a relevant correlation with IAM data (Escuder-Gilabert, L. et al., 2000), 
revealing that active compounds had the same kind of lipophilicity. A larger set of compounds was 
investigated using IAM and other molecule descriptors against three antitumor in vitro cell tests. A 
clear difference between three cell-test models of antiproliferation activity was detected. The IAM, 
as parameter for lipophilicity, only revealed to be a descriptive for activity with the T47D cell 
model and not in models using SW707 or A549 cells (Matysiak, J. et al., 2007). Hopefully, these two 
examples show how lipophilicity tests might help in understanding activity results and even guide 
early drug discovery. 
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2.2 N-in-one measurements 
 
2.2.1 The principle of n-in-one 
 
 
Historically, the identification of new pharmacologically active hit compounds in drug discovery 
has used mixtures and cocktails. Combinatorial chemical synthesis has screened unspecified 
libraries (mixtures) for pharmacologically active leads, and has identified and purified only active 
compounds. Activity screening methods have also been developed for mixture analysis, such as 
immobilised receptors. Unfortunately these experiments still have problems with false positive and 
false negative results  (Shin, Y.G. and van Breemen, R., 2001). Currently, compounds are more often 
purified before actual activity screening, because purification reduces false positive results (Isbell, J., 
2008). Lately, research has tended to focus on parallel systems rather than on combinatorial 
chemistry mixtures. Nevertheless, Triolo and Kennedy point out in their papers that combinatorial 
chemistry has had rather significant effects on synthetic planning and analytical solutions (Triolo, A. 
et al., 2001, Kennedy, J.P. et al., 2008). It is important to understand what other impacts n-in-one has 
had. 
 
In drug discovery the focus is on the selection of appropriate and potentially valuable compounds 
for next developmental stage. Single (parallel) and n-in-one approaches are described in the table 
below (Table 2). In the n-in-one approach, potential compounds are selected as early as possible, 
but experimental planning is more complex, the result might have some average meaning and 
validation of the method for mixtures is an important part of the process. 
 
 
Table 2. Limitations and benefits in the n-in-one approach and traditional single compound analysis 
in the drug discovery selection process: planning, analysing, interpreting and reporting the results. 
 
 
Single N-in-one 
One simple  Complex 
Exact results Sometimes an average result, 
but inter-test variability is reduced 
Useful for understanding details A spirit of going forward 
Creates a lot of (extra) work Rapidly provides a bigger picture  
 
 
Cocktail dosing in pharmacokinetic experiments was started in 1990 by researchers at Glaxo 
Wellcome (Berman, J. et al., 1997). Recently, two excellent reviews have been published on 
pharmacokinetic studies using cocktail dosing (Smith, N.F.  et al., 2007, He, K. et al., 2008). In the past 
20 years, knowledge of the benefits and limitations of n-in-one measurements has increased. 
Manitpisitkul and White assessed the feasibility of the n-in-one approach in drug discovery 
(Manitpisitkul, P. and White R.E., 2004). However, their claim that approximately half of drug 
development companies favour the approach and half are against it appears a little “black & white”. 
Although the research scope was rather small, it remains clear that use of n-in-one should not be 
underestimated. 
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Many methods have been presented as n-in-one (Figure 4), and the definitions of the analysis are as 
follows: 
 
a) In cocktail dosing, before biological assay, compounds are combined. Mixtures are also 
referred to as cassettes or cocktails. Compounds are assayed and analysed as a cocktail, 
which means that biological results should also be interpreted as a mixture. 
b) In pooled cocktail analysis, biological assays are conducted separately for each compound. 
After biological assays, the samples of different compounds are pooled and analysed in as 
cocktails. Results of biological assay can be interpreted individually, but the analytical 
method needs to be valid for a mixture analysis. 
c) Samples including the same compounds can also be pooled. Compounds are assayed 
separately and combined before analysis. This reduces chemical analysis and helps if the 
sample amount is limited. Even though the information for an individual sample is missed, 
different time points can be summarised as classifying parameters. Different time points are 
also analysed as mixtures for qualitative analysis. 
d) Parallel methods are sometimes also referred to as n-in-one analysis, but in reality they have 
a singe compound in each vessel. In these studies, parallel or generic analytical methods are 
usually developed. 
 
2.2.2 Cocktail dosing, mixtures (biological n-in-one) 
 
In vivo pharmacokinetics is the study of a compound’s behaviour in the body. The aim of early 
studies is to collect results that are exact enough for compound selection, for example using cocktail 
dosing. To have evidence for this, the pharmacokinetics of nine compounds were tested using single 
and cocktail dosing by Allen and co-workers (Allen, M.C. et al., 1998). The results for the AUC (area 
under the curve of a concentration versus time plot) and the Cmax (maximum concentration in 
plasma) were compared following dosing with single compounds or mixtures of five compounds. 
The rank order of exposure was similar, even though AUC was 45% higher in cocktails. Cmax was 
only 9% higher in cocktails than in single dosing, tested using a control compound. Another 
research group also reported that the AUC and half life were greater using cocktail dosing versus 
single dosing for some compounds (Smith, N.F. et al., 2007). 
 
Researchers from the Bristol-Myers-Squibb drug company also investigated the in vivo 
pharmacokinetics of several lead compounds using mixtures (He, K. et al., 2008). The best 
correlation was achieved for the volume of distribution and renal excretion (r = 0.91 and 0.83, 
respectively), with a lower correlation for systemic clearance (r = 0.69) and the lowest for oral 
bioavailability (r = 0.53). In their studies the pharmacokinetics in different animals (rats, dogs and 
chimpanzees) were significantly correlated between single and cocktail dosing. 
 
Smith et al. reported both positive and negative experiences with cocktail dosing (Smith, N.F. et al., 
2007). In some cases, the discovery process was accelerated when n-in-one was used, but in some 
compound classes, compound-compound interactions appeared and the rank order of the 
compounds also changed. The group additionally studied in vitro metabolism using hepatocytes. 
They found lower levels of metabolism in microsome incubations with n-in-one than in single 
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compound experiments. This was interpreted as one or more compounds inhibiting the metabolism 
of the others. Although the inhibition of metabolism sometimes exists, metabolic clearance studies 
have been successfully carried out cocktail dosing (Hakala, K. et al., 2005). In addition to small 
doses, the cocktails have been limited to compounds that do not have metabolic interactions with 
the main cytocrome P450 enzymes (CYP) (White, R.E. and Manitpisitkul, P., 2001). Smith and 
coworkers also mentioned that cocktail studies should be regularly validated with different 
compound classes (Smith, N.F. et al., 2007). 
 
 
 a) Cocktail dosing b) Pooled cocktail analysis
 
 
c) Pooled analysis of samples  d) Parallel analysis  
Figure 4. Nomenclature of single and n-in-one methods: Biological tests are performed n-in-one in 
cocktail dosing (a). Analytical tests are performed n-in-one when; b) pooled analysis is carried out 
using cocktails, or c) pooled analysis of samples is conducted. In addition, d) parallel “single” 
analysis can be used. 
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Plasma protein binding (unbound/bound concentration ratio of a compound in blood) has an 
important effect on pharmacokinetics, because pharmacokinetic parameters are usually a function of 
the unbound fraction of a drug. Human serum albumin (HSA) is the most abundant protein in 
blood, and protein binding parameters can be calculated from retention factors using an 
immobilized HSA column. The latest method using an HSA column is comparable with older 
methods such as ultrafiltration and dialysis (Cheng, Y. et al., 2004). An n-in-one study demonstrated 
that 10 compounds can be measured using a HSA gradient run (Liu, H. et al., 2002). However, little 
information was provided on whether the single and n-in-one experiments correlated. It remains 
unclear whether possible compound-compound interactions exist in protein binding. Moreover, 
when the validation is not reported, a more important question is whether the results of n-in-one are 
method-dependent. 
 
Smaller concentrations are favoured in cocktail dosing, because certain undesired compound-
compound interactions are minimised. In the example of Caco-2 absorption studies, with low 
sample concentrations, three different approaches have been presented: single compound, sample 
pooling and cocktail dosing. In these studies the same results have been obtained with single and n-
in-one methods (Bu, H.-Z. et al., 2000). A general expectation nowadays is that coexistence of 
compounds that are substrates or inhibitors of P-glycoprotein transporters might cause compound-
compound interactions. Recently, a mixture of ten compounds, five of which were P-glycoprotein 
substrates, showed that one had different responses in single compared to cocktail dosing (Smalley, 
J. et al., 2006). Even though Smalley et al. claimed that the substrate concentration was as low as 
3μM, it might be argued that this was too high. 
 
In an article describing how early pharmacokinetic data from mice were investigated using cassette 
dosing, some of analyses could not be performed. Because of the limited amount of blood, the 
smaller dose in the cocktail and too low concentrations in blood, analysis was problematic 
(Watanabe, T., et al, 2006). A serious problem in comparing the results of individual and n-in-one 
analysis might be the lack of analytical sensitivity. With low concentrations, greater sensitivity is 
usually needed in analytical methods. 
 
Ethically, cocktail dosing is at its best when it minimizes the number of test animals. As previous 
examples have shown, cocktail dosing is still controversial because of potential compound-
compound interactions, such as the competitive inhibition of drug-metabolizing enzymes, 
transporter proteins or perhaps even plasma protein binding, which may lead to false negative as 
well as false positive results (Smith, N.F. et al., 2007). No report has clearly stated that the risks are 
smaller using in vitro tests, but at least fewer parameters then need to be validated. Moreover, in 
vitro testing using cell cultures of human origin might be beneficial compared to some animal 
models. 
 
Because of the risk of compound-compound interactions, especially in in vivo cocktails, attempts 
have been made to eliminate interaction via the study design. Cocktail dosing is usually limited to 
small concentrations, only few compounds, and to compounds that are known to have no 
interactions (White, R.E. and Manitpisitkul, P., 2001). Moreover, as previously mentioned, because of 
the poor correlation of oral bioavailability between single and cocktail dosing (He, K. et al., 2008), 
the use of intra venous administration and control compounds in the mixtures is encouraged (Huang, 
R. et al., 2004). Another precaution has been recommended for the administration of cocktails. The 
formulation of several compounds in a single dosing solution might be challenging if they include 
poorly soluble substances. Several researchers have noted that solutions should be checked for 
compound precipitation (He, K. et al., 2008, Smith, N.F. et al., 2007). 
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In addition to early drug discovery, a similar approach to n-in-one has been employed in later 
phases. Mixtures of several compounds for different cytochrome P450 (CYP) isoforms were 
evaluated and presented in a research paper by Turpeinen and coauthors (Turpeinen, M. et al., 2005). 
Drug-drug interactions are tested using biological n-in-one. Such interactions are usually thoroughly 
studied before clinical trials. To achieve better success rates in drug development, some tests might 
also be included earlier, such as inhibition of CYP3A4 enzymes (He, K. et al., 2008). 
 
In addition to the validation of different compound series suggested earlier, n-in-one has also been 
used for the method validation of Caco-2 experiments. An article by Koljonen and coworkers 
(Koljonen, M. et al., 2006) reported that it is beneficial to standardise the permeability experiment, 
because of variability between Caco-2 cell batches and potential P-glycoprotein candidates. The 
control compounds could be, for instance, some of the 20 compounds suggested for passive 
permeability classification in FDA guidelines (Waiver of in vivo bioavailability and bioequivalence 
studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, 
2000). These also include verapamile, a known marker of P-glycoprotein transport. One selection of 
these compounds has also been published with the quantitative liquid chromatography tandem mass 
spectrometry (LC/MS/MS) methods (Hakala, K. et al., 2003). 
 
2.2.3 Pooled cocktail analysis (analytical n-in-one) 
 
A further attempt to eliminate interaction problems is pooled cocktail analysis, in which different 
compounds are pooled just before analysis. In Pfizer research, three different pharmacokinetic 
samples of plasma or brain tissue were pooled and analysed using cocktails (Atherton, J. et al., 1999). 
Chromatographic separation with fluorometric detection was performed and validation gave 
accurate and repeatable results for all n-in-one analysis. The literature also shows that serum or 
plasma samples of three rats have been pooled and then analysed using liquid chromatography and 
ultra violet detection (LC-UV). Data for AUC curves were obtained in a time required by 
conventional single compound analysis (Kuo, B.-S. et al., 1998, Singh, R.P. et al., 2005). 
 
Hsieh and co-workers pooled plasma samples two times to increase throughput (Hsieh, Y. et al., 
2002). Six samples of equal time points, but different compounds, were pooled. These samples were 
pooled with samples from another study, making a total of 12 compounds in a single cocktail. 
However, small amounts of plasma might be difficult to pipette. In addition, each time the 
concentrations of compounds in plasma will decrease. For repeatability and sensitivity reasons, at 
some point, extra pooling is too much. Smaller animals, such as mice, have a limited blood volume. 
The use of a smaller sample volume is appreciated when the rest of the sample is needed for other 
studies. 
 
2.2.4 Pooled analysis of samples (analytical n-in-one) 
 
Metabolic stability has been estimated for compounds using in vitro microsome incubations and 
pooled analysis (Zhao, S. et al., 2005). The same compound but different time points were pooled 
before analysis. To accelerate the analysis, the curve values (t1/2) were calculated using fewer data 
points. This allowed the researchers to select sample volumes convenient for their experimental 
approach. In addition, a certain amount of the samples was saved for other studies, such as 
qualitative screening of metabolites. The n-in-one method was also compared with the single 
approach and correlated well. 
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In addition to in vitro metabolic research, in vivo pharmacokinetic studies have used plasma pooling 
of different time points. When plasma samples of all time points have been pooled, the 
concentration achieved has been equivalent to the area under curve (AUC) (Hop, C.E. et al., 1998). 
Furthermore, analysis has been reduced from seven data points to three, and both AUC and Cmax 
values could be derived with less sample analysis (Han, H.-K. et al., 2006). 
 
2.2.5 Parallel and other analytical solutions 
 
If experiments are performed in single vials, parallel or other analytical techniques can be used to 
increase the throughput, such as automated sample preparation procedures using 96-well plate 
formats. For example, Jenkins and co-workers reported automatic liquid handling in a well plate 
format and liquid chromatography - mass spectrometry (LC-MS) analysis for metabolic assays 
(Jenkins, K.M. et al., 2004).  
 
The multiplexed electrospray interface (MUX) was described as analytical n-in-one method by 
Fang and co-workers (Fang, L. et al., 2002). In this method, eight chromatographic columns were 
connected to one pump and one mass spectrometer. Eight compounds or eight time points in total 
could be analysed at once and each run was recorded in an individual file. MUX technology with 
four sprayers has also been used for cytochrome P450 enzyme (CYP) inhibition studies at Schering-
Plough Research (Chu, I. and Nomeir, A.A., 2006). 
 
The principle of n-in-one can be interpreted in different ways. Sadagopan and Ohkawa with their 
colleagues have reported on generic method development for plasma analysis. Generic methods are 
ideal for the early discovery phase, because the compounds in one compound family are usually 
similar (Sadagopan, N. et al., 2005, Ohkawa, T. et al., 2003). Both teams have described their method as 
being valid for multiple analytics. Some generic methods have already been developed for mixtures 
in cassette dosing (Mensch, J. et al., 2007). Metabolic screening tests are also interpreted as n-in-one 
if several unknown metabolites are screened (Li, A.C. et al. 2007). Furthermore, biomarker screening 
might be seen as n-in-one analytics in drug discovery (Geoghegan, K. and Kelly, M.A., 2005) when 
several markers are followed in a single run. 
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2.3 The separation of liquid chromatography mass spectrometry 
 
2.3.1 Definitions for specificity, sensitivity and selectivity 
 
The terms specificity, sensitivity and selectivity are commonly used in diagnostic tests and in the 
validation of drug analysis. Here, three definitions presented in the guidelines of the Food and Drug 
Administration (FDA) are quoted; the first is also included in the guidelines of the International 
Conference on Harmonisation (ICH) on technical requirements for the registration of 
pharmaceuticals for human use. 
 
The following definition is presented in the FDA documents Guidance for Industry, Validation of 
Analytical Procedures: Definition and Terminology, Guidance for Industry, Text on Validation of 
Analytical Procedures, ICH-Q2A, in addition to the ICH Harmonised Tripartite Guideline, 
Validation of Analytical Procedures: Text and Methodology Q2 (R1): 
 
“Specificity is the ability to assess unequivocally the analyte in the presence of components which 
may be expected to be present. Typically these might include impurities, degradants, matrix, etc. 
Lack of specificity of an individual analytical procedure may be compensated by other supporting 
analytical procedure(s). 
This definition has the following implications: 
Identification: to ensure the identity of an analyte. 
Purity Tests: to ensure that all the analytical procedures performed allow an accurate statement 
of the content of impurities of an analyte, i.e. related substances test, heavy metals, residual solvents 
content, etc. 
Assay (content or potency): to provide an exact result which allows an accurate statement on the 
content or potency of the analyte in a sample.” 
 
Guidance for Industry and FDA Staff, Statistical Guidance on Reporting Results from Studies 
Evaluating Diagnostic Tests states: 
 
“In studies of diagnostic accuracy, the sensitivity of the new test is estimated as the proportion of 
subjects with the target condition in whom the test is positive. Similarly, the specificity of the test is 
estimated as the proportion of subjects without the target condition in whom the test is negative (see 
the Appendix for an example of this calculation).” 
 
Guidance for Industry, Bioanalytical Method Validation presents: 
 
“Selectivity is the ability of an analytical method to differentiate and quantify the analyte in the 
presence of other components in the sample. For selectivity, analyses of blank samples of the 
appropriate biological matrix (plasma, urine, or other matrix) should be obtained from at least six 
sources. Each blank sample should be tested for interference, and selectivity should be ensured at 
the lower limit of quantification (LLOQ).” 
 
These are also the definitions used in the following, even though the analytical applications are 
different. The reasons why liquid chromatography mass spectrometry (LC-MS) methods can be 
seen as sensitive and selective for early drug discovery analysis are exemplified in next chapters. 
Mass spectrometry was the selected instrument for the analysis in this thesis, because it is more 
specific than many other detectors. 
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2.3.2 Mass spectrometric separation 
 
Liquid chromatography – tandem mass spectrometry (LC-MS/MS) using triple quadrupole (QqQ) 
instruments provides high sensitivity and selectivity for n-in-one samples. The mass spectrometric 
separation involves mass-to-charge ratio (m/z) analysis, fragmentation and aspect of ionisation. The 
following examples are for triple quadrupole instruments, which were used in the experimental 
studies of this thesis. 
 
The flow from liquid chromatography (LC) is introduced to a mass spectrometer using interfaces. 
The two most common interfaces used with LC are electrospray ionisation (ESI) and atmospheric 
pressure chemical ionisation (APCI). Although a universal detector is what is wanted, ionisation of 
mass spectrometry causes limitations.  The negative ion mode is usually better utilised for acidic 
compounds and the positive ion mode for basic compounds. ESI, where ion formation is also in the 
liquid phase, is more compatible for ionic molecules and polar compounds (containing heteroatom, 
acid and basic organic compounds). APCI, where ions are formed mostly in the gaseous phase, is 
more often used with small, moderately polar or nonpolar compounds. Thermally labile compounds 
cannot be detected by APCI. Atmospheric pressure photo ionisation (APPI) is a new technique that 
is suitable for also for some neutral non-polar compounds. Gas phase ionisation involves the 
transfer or abstraction of protons, adduct attachments, charge exchange and electronic capture 
reactions. In ESI ionisation, which is softer ionisation than APCI, adducts and cluster ions are also 
more often formed. Ionisation energy and proton affinity provide better understanding of ionisation 
efficiency in the LC-MS methods. Usually, these differences are well understood by the method 
developer. Ionisation with ESI, APCI and APPI interfaces are discussed in detail in a new review by 
Kostiainen and Kauppila (Kostiainen, R. and Kauppila, T., 2009). 
 
The ionisation efficiency depends on how well ions are formed. Non-volatile buffers and matrix 
compounds (such as salts, proteins and other analytes) might enhance or suppress the ionisation and 
even disturb the analysis (Taylor, P.J., 2005). Buffers commonly used in liquid chromatography may 
strongly suppress ionisation in ESI, leading to significantly decreased sensitivity. APCI tolerates 
much higher buffer concentrations than ESI ionisation (Schuhmacher, J. et al., 2003). The three-
dimensional structure of the ionisation probe and the electronics also influence the matrix effects in 
mass spectrometry (Mei, H. et al., 2003). If the matrix suppression is intense, sample pre-treatment 
before MS analysis should considered. Sample cleaning and separation by liquid chromatography is 
introduced in next chapter, while other sample pre-treatments, which depends on the sample matrix, 
are not discussed here. 
 
A mass spectrometer distinguishes compounds according to their mass per charge ratios (m/z). Only 
isobaric compounds have the same exact mass, which is mainly problematic with some peptides. A 
single quadrupole has one quadrupole mass selector in which the characteristic ions of a molecule 
are detected. Triple quadrupoles (QqQ) use two quadrupole mass selectors, and between them there 
is a quadrupole chamber for collision-induced dissociation (CID). Isobaric compounds with 
different fragmentation patterns can also be separated in QqQ. 
 
 
Triple quadrupole (QqQ) instruments can be operated in different modes (Figure 5): 
 
a) Positive or negative ions of introduced compounds can be detected as a mass spectrum. The 
molecule ion of a compound, [M-H]- or [M-H]+, is important for compound recognition. By 
directly introducing a complex mixture and analysing ions characteristic of a compound, it is 
possible without any other separation method to determine the presence of the compound. 
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This is documented in the combinatorial library screening, where the use of the molecular 
weight with isotopic pattern information gave tools to manage huge amount of 
identification, purity and synthetic yield information gathered. Yates and co-workers have 
used estimated and analyzed peak intensities as a prioritising tool and the best synthesised 
libraries were possible to screen first (Yates, N. et al., 2001).  
 
However, it is important to understand that exact mass measurements and the identification 
of elemental compositions are mainly performed using magnetic sector instruments, fourier 
transform ion cyclotron resonance mass spectrometers and time of flight (TOF) instruments, 
and not with quadrupole instruments. Triple quadrupole mass spectrometers are commonly 
integrated with liquid chromatography and employed as detectors. The extracted ion 
chromatograms of mass spectra are able to show profiles of different ions, even for co-
eluting peaks. 
 
b) Mass fragmentation can be studied using a product ion scan, also known as a daughter ion 
scan. The selected molecular ion gives fragments during collision and all product ions are 
detected. This is usually used for qualitative analysis, in which it provides structural 
information. 
The usual molecular ions in the ionisations of electrospray ionisation (ESI) and atmospheric 
pressure chemical ionisation (APCI) have an even electron structure, and they are more 
stable than odd electron ions. Therefore, before fragmentation, molecular ions often form 
the biggest peaks in the spectra, which is advantageous. Characteristic isotope patterns may 
also be used in interpreting the spectrum of an unknown compound. Typical fragmentation 
reactions include single-bond cleavages, fragmentations with hydrogen rearrangements and 
skeletal reorganization with the extrusion of stable neutrals, although hydrogen 
rearrangement reactions usually need specific geometries to appear (Williams, D.H.; and 
Fleming, I., 1989). 
 
Structural information from the product ion scan depends not only on the chemical structure, 
but also on the collision energy and multivariate physicochemical properties, for example 
charge localization and stabilisation of the compound. The collision-induced dissociation 
(CID) of gas phase ions is an energy-selected system; statistically, the weakest bond splits 
first. Ab initio calculations have been used to estimate the energy differences, as reported by 
Armentrout and Baer, as well as Lifshitz (Armentrout, P.B. and Baer, T., 1996, Lifshitz, C., 
2001). In these calculations, the energies, structures and vibrational frequencies of stable and 
transient species are used in virtual estimation together with fragmentation data. 
 
c) A precursor ion scan, also known as a parent ion scan, analyses all the ions that produce the 
wanted fragment ion (m/z) in collision. 
 
d) A neutral loss scan selects all ions whose fragmentation gives the wanted neutral molecule 
loss in collision, i.e. the neutral fragment. Precursor and neutral loss modes are both used to 
detect compound classes. These modes are used for screening phase 1 metabolites (Li, A.C. 
et al. 2007 and Xu, X. et al. 2004) and conjugative phase 2 metabolites (e.g. glucuronides) (Liu, 
D.Q. et al. 2002). Glutathione conjugate screening is important in finding possible reactive 
metabolites (Shuguang, M. and Subramanian, R., 2006). These modes also give a signal for 
some compound classes, such as acylcarnitines, in complex combinatorial chemistry 
mixtures (McClellan, J.E. et al., 2002). 
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e) In monitoring selective reactions, the wanted molecular ion fragments during collision and 
the selected ion are detected. Several reactions are quite regularly monitored simultaneously 
after each other. Selective reaction monitoring (SRM) is mainly used in quantitative 
research. Quantitation with triple quadrupole instruments has usually increased sensitivity 
compared to single quadrupole instruments, because the signal/noise ratio is improved. 
 
 
 
 
 
 
Figure 5. Different scanning modes using a triple quadrupole mass spectrometer: a) mass spectrum, 
b) product ion scan, c) precursor ion scan, d) neutral loss scan and e) selected reaction monitoring; 
(CID = collision-induced dissociation) 
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2.3.3 Liquid chromatography methods in early studies 
 
Analytes in a complex mixture can be isolated before detection using chromatographic separation. 
The isolation of compound increases both the sensitivity and selectivity. This is especially 
important for mass spectrometric analysis because chromatographic separation can, among other 
effects, limit signal suppression caused by the matrix effect. Chromatography is based on retention 
and resolution (k and α). Even though basis of the separation lies in chromatographic columns and 
different stationary phases, this chapter presents practical aspects of method development other than 
solid phase chemistry. Unger et al. explain some common chromatographic parameters in their 
review (Unger, K. et al., 2008), and these are presented in Table 3. These equations are a simple and 
straightforward for improving analytical methods. Programs for method development use 
parameters in their simulation of a chromatographic run.  
 
During 30 years (from 1970 to 2000) the particle sizes of columns have dramatically diminished 
from 30 µm to less than 2 µm. A smaller particle size usually gives better resolving power (Rs) by 
affecting the column plate number (N). Raising the flow-rate (u) gives more rapid analysis. 
Unfortunately, with smaller particle columns (dp), the consequently higher back pressure (∆p) might 
be a problem. For high pressures the ultra pressure liquid chromatography (UPLC) has been 
developed. All new methods developed with UPLC instruments have been published, including 
those in the ADME area (Mensch, J. et al., 2007, Pedgraglio, S. et al., 2007, Plumb, R.S. et al., 2008). 
 
 
Table 3. Basic chromatographic parameters and their equations, as presented here, can help in 
method development. 
 
Retention factor (k): 
 
k = (tr - t0)/t0, 
tr = retention time, t0 = void volume time  
Resolution (Rs): 
 
Rs = (1/4) (α-1) (N1/2 k) / (1+k); 
k = retention factor, N = column plate number, α = separation factor (k2/k1) 
Kinetic properties and peak dispersion (H and N): 
 
H = theoretical plate height, N = number of theoretical plates 
Hydrodynamic properties such as pressure change (∆p): 
 
∆p = ΦηLu/dp2; 
Φ = column resistance factor, η = viscosity of the eluent, L = column length, 
u = linear velocity of eluent, dp = average particle diameter of the packing material 
 
 
A shorter column (L) gives a smaller pressure. Therefore, small cartridge columns have been used 
for Caco-2 permeability samples to provide rapid sample pre-treatment before MS detection (Bu, 
H.Z. et al., 2000). This method cleaned the sample matrix, but the compounds were only separated by 
mass spectrometry and not using chromatography. In addition to short columns, lower viscosities 
(η) of the mobile phase have also been used to lower the pressure. Furthermore, higher column 
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temperatures, when effective, are used to change the column pressure. Even if columns with 
different dimensions and materials can be selected, Zhao and co-workers admitted in their article 
that solvent composition and column temperature modifications are usually decided on method 
development for practical reasons (Zhao, J. and Can, P.W., 1999). This depends on how much time is 
available for method development. 
 
The main streams in the development of chromatographic columns during the last 50 years have 
involved two types of sorbent materials: packed particle beds and monolith structures. In addition, 
nonporous particle columns with porous surface have been developed and used as Halo columns 
(Marchetti, N . et al., 2007). Monolithic columns are porous rods (Unger, K.K. et al., 2008). A similar 
hydrodynamic equation to that for particle columns is invalid for monolith columns, but faster 
separation can be achieved at low pressures. Monolith columns are important for high flow rate 
analysis, as mentioned in P450 inhibition screening assays (Peng, S.X. et al., 2003). 
 
Small particle columns with mass spectrometry gives better sensitivity compared to traditional 
detectors when only a small sample amount is available (Plumb, R.S. et al., 2008). The basic 
chromatographic equations, which are valid for particle columns, can be used especially for up- or 
downscaling of methods, and this is an advantage for rapid method development. 
 
2.3.4 Mass spectrometry compared to other detectors 
 
In characterising synthetic compounds, as combinatorial libraries, mass spectrometry (MS) is used 
with other detectors. Comparable results are achieved by evaporative light scattering (ELSD), 
chemiluminescent nitrogen (CLND), corona charged aerosol (CAD, charged aerosol detection) or 
nuclear magnetic resonance detectors (NMR) (Yurek, D.A. et al., 2002, Zhang B. et al., 2008). If no 
pure analytical standards are present, the capability of CLND to quantify the molar amount of 
compounds containing nitrogen is beneficial. NMR detectors, which give elevated qualitative 
information, have the disadvantage of high expense. ELSD can also be used, although the 
nebulization has to be optimised and the temperature should be below the melting point of the 
detected compounds. CAD is newer, more sensitive compared to ELSD and a competitor for 
traditional ultraviolet (UV) detectors. In a combination of ultraviolet (UV) and MS, product 
identification is achieved by MS and the relative purity of products is determined by UV (Fang, L. et 
al., 2002). Sometime, UV detection gives better linearity in the high concentration range, but 
products and side-products often also possess equal absorption. Letot and co-workers criticised that 
results for the total amount of a compound might be inexact if the compound elutes in the void 
volume of the column and is excluded from UV or MS data (Letot, E. et al., 2005). However, this 
problem is quite common for all methods using chromatographic columns. 
 
In quantitative analysis, ultra violet (UV) or fluorescence detection methods give good analytical 
parameters such as linearity, accuracy, precision and repeatability. A problem with UV is its poor 
sensitivity, and sometimes also the poor selectivity. Cocktail analysis easily increases the limit of 
detection when the total sample volume is fixed. Moreover, small substrate concentrations are 
common in the cocktails, because of the risk of compound-compound interactions. Rajanikanth and 
co-workers noted that signals might overlap and metabolites of compounds might interfere in both 
fluorescence and UV methods, especially in vivo cocktail dosing studies (Rajanikanth, M. et al., 
2001). Some methods use both mass spectrometric and UV/fluorescence detection. In a Caco-2 
study, the fluorescence and mass spectrometry (MS) methods had 5-10 times better sensitivity 
compared to UV (Bu, H-Z. et al., 2000). Different detector sensitivities were employed in study by 
Palmgren and coworkers, where UV and fluorescence were combined. In the analysis of Caco-2 
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samples, fluorescence detection was used for low concentrations and UV detection for higher 
concentrations (Palmgren, J.J et al., 2004). However, the lack of fluorescence is a limitation and 
restricts its use. In mixture pharmacokinetics, with cocktail dosing or plasma pooling, the 
possibility of interference from drug metabolites increases. More selective method, as mass 
spectrometry, is an advantage, even though ion suppression of the matrix and unknown metabolites 
has to be kept in mind (Sadagopan, N. et al., 2005, Ohkawa, T. et al., 2003). 
 
The use of mass spectrometry (MS) compared to ultra violet (UV) detection has increased in the 
past few years. As described earlier, the parallel artificial membrane permeability assay (PAMPA) 
has grown in popularity over Caco-2 absorption samples because of its easier implementation in 
high throughput analysis, as also reported by Praveen et al. (Praveen, V. et al., 2006). Even though 
Hämäläinen and coworkers noted that UV readers are fast, they still may have limited sensitivity, 
and components that are unstable may give unspecific results (Hämäläinen, M.D. et al., 2004). When 
PAMPA permeability studies were analysed with UV, Mench and coworkers also had difficulty in 
determining the tested compounds, mainly because of poor solubility or the low UV response. 
When they changed to an automated LC-MS instrument, the capability to estimate PAMPA 
coefficients rose by over 50% (Mensch, J. et al., 2007). Several other mixture analyses using mass 
spectrometry have been developed for metabolism studies, as for the UDP-glucuronosyl transferase 
(UGT) isoenzyme with cocktails (Hakala, K.  al., 2005). 
 27 
 
3. Aims of the studies 
 
New drug discovery technologies, such as analysis using n-in-one, require proper planning and 
appropriate analytical methods. The aims of the studies reported here were to investigate ways of 
using n-in-one measurement, mixing and pooling of samples to give better sample throughput and 
to describe analytical solutions in n-in-one. The compounds in the studies were test compounds: a 
component from a synthesised combinatorial library or a mixture of commercial drug molecules. 
Selected compounds for lipophilicity and absorption screening tests included acids and bases, and 
they were small organic drugs. Three separate mass spectrometric studies were designed to give 
good examples of new methods in the field of n-in-one and drug discovery analytics: combinatorial 
chemistry libraries, lipophilicity and absorption screening. 
 
The more specific aims of the research (A-C) were 
 
 
A. To characterise mass spectrometric fragmentation patterns for ten 
nitrophenoxy benzoate compounds made by combinatorial chemistry 
synthesis, to study the influence of nitro substituents and alkyl chain length on 
collision-induced fragmentation and to demonstrate the precursor ion scan 
spectra of compounds. Compounds in the study were individually synthesised 
but pooled before the last library screening analysis. 
 
 
 
 
B. To compare immobilized artificial membrane (IAM) chromatography 
retention factor k (log kIAM values) using phosphate buffer and ammonium 
acetate buffer with ultraviolet (UV) detection and single compound analysis. 
Furthermore, to develop IAM chromatography with mass spectrometric (MS) 
detection for nine compounds, and to compare IAM chromatography retention 
factor k (log kIAM -values) of single compound analysis and UV with n-in-one 
analysis and MS using atmospheric pressure chemical ionization (APCI). In 
addition, to demonstrate fast lipophilicity screening using MS, n-in-one and a 
gradient run of nine small organic drugs, including both acidic and basic 
compounds. 
 
 
 
 
C. To develop a rapid and sensitive liquid chromatographic method with mass 
spectrometric (SRM) detection for ten small organic drugs, including both 
acidic and basic compounds, using electrospray ionization (ESI) for Caco-2 
analysis. 
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4. Experimental 
 
4.1  Chemicals and reagents 
 
Nitrophenoxy bentzoates were synthesized by the synthetic group of the Division of Pharmaceutical 
Chemistry. The general procedure for the synthesis of the compounds was the following: The alkyl 
3,5-dihydroxybenzoates needed for the subsequent etherification procedure were prepared by acid-
catalysed etherification of commercially available 3,5-dihydroxy benzoic acid. Reaction with p-
dinitrobenzene or o,p-dinitrobenzenechloride in the presence of potassium carbonate in acetone 
produced the corresponding alkyl 3-hydroxy-5-(4’-nitrophenoxy) benzoates or alkyl 3-hydroxy-5-
(2’,4’-dinitrophenoxy) benzoates, respectively (Figure 6) (Bird, C.W. and Latif, M., 1980). A full 
interpretation of the 1H and 13C NMR shifts and coupling constants of spectra recorded on a Varian 
Fourier transform NMR spectrometer at 500 and 125 MHz revealed that the target compounds had 
been successfully synthesised in total yields of 27 - 54%.  
 
Compounds used in immobilized artificial membrane (IAM) and Caco-2 studies were purchased. 
The structures of studied compounds are presented in Figure 7 and the chemicals and reagents are 
listed in Tables 4 and 5. 
 
 
Compound R1 R2 
A1 CH3 H 
A2 C2H5 H 
A3 C3H7 H 
A4 C4H9 H 
A5 C5H11 H 
B1 CH3 NO2 
B2 C2H5 NO2 
B3 C3H7 NO2 
B4 C4H9 NO2 
B5 C5H11 NO2 
 
 
 
OO
NO2
O
R2
R1
O
 
 
 
 
Figure 6. Structures of nitrophenoxy benzoate compounds studied in publication A. 
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Figure 7. Compounds and their structures studied in publications B and C were the following: 
a) buspirone, b) hydroxyzine, c) ibuprofen, d) indomethacin, e) ketoprofen, f) midazolam, g) 
naproxen, h) phenazon, i) phenobarbital, j) procaine, k) propranolol, l) thioridazine, m) timolol and 
n) verapamil 
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Table 4. Compounds studied in immobilized artificial membrane (IAM) chromatography and in the 
Caco-2 study, publications B and C. The negative logarithm of the dissociation constant Ka (pKa), 
HA for acids and HB+ for bases, is also presented (Lemke, T. et al. 2008). 
 
 
Compound pKa Manufacturer/Purchased  Publication 
Buspirone _ Sigma Chemical Co, St Louis, MO, 
USA 
C 
Hydroxyzine  2.0 (HB+) Sigma Chemical Co, St Louis, MO, 
USA 
C 
Ibuprofen 5.2 (HA) University Pharmacy, Helsinki, Finland B 
Indomethacin 4.5 (HA) Orion Oyj, Espoo, Finland B 
Ketoprofen 4.8 (HA) Medifon, Helsinki, Finland B 
Ketoprofen (same) ICN Biomedical Inc., Aurora, OH, USA C 
Midazolam 6.2 (HB+) Hoffman-la Roche, Basle, Switzerland B, C 
Naproxen 4.2 (HA) ICN Biomedical Inc., Aurora, OH, USA C 
Phenazon 
(Antipyrine) 
1.5 (HB+) Aldrich Chemical Company Inc, 
Milwaukee, WI, USA 
C 
Phenobarbital 7.4 (HA) University Pharmacy, Helsinki, Finland B 
Procaine 
hydrochloride 
6.8 (HB+) University Pharmacy, Helsinki, Finland B, C 
Propranolol 
hydrochloride 
10.4 (HB+) Orion Oyj, Espoo, Finland B 
Propranolol 
hydrochloride 
(same) ICN Biomedical Inc., Aurora, OH, USA C 
Thioridazine 
hydrochloride 
9.5 (HB+) Orion Oyj, Espoo, Finland B 
Timolol maleate 8.8 (HB+) University Pharmacy, Helsinki, Finland B 
Timolol maleate (same) Orion Oyj, Espoo, Finland C 
Verapamil 
hydrochloride 
3.5 (HB+) ICN Biomedical Inc., Aurora, OH, USA C 
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Table 5. The list of reagents used: All organic solvents and other reagents were of analytical or 
chromatographic grade. 
 
Reagents Manufacturer Publication 
Milli-Q water from water 
purification system 
Millipore, Molsheim, France A, B, C 
methanol Rathburn, Walkerburn, UK A 
acetonitrile Rathburn, Walkerburn, Scotland B, C 
ammonium hydroxide Merck, Darmstadt, Germany A, B 
potassium dihydrogen 
phosphate 
Merck, Darmstadt, Germany B 
disodium hydrogen 
phosphate dihydrate 
Merck, Darmstadt, Germany B 
phosphoric acid Merck, Darmstadt, Germany B 
potassium chloride Merck, Darmstadt, Germany B 
sodium chloride Merck, Darmstadt, Germany B 
ammonium acetate Merck, Darmstadt, Germany B, C 
sodium nitrite Riedel-de Haën, Seelze, Germany B 
formic acid  Merck, Darmstadt, Germany C 
Dulbecco’s phosphate-
buffered saline 
Gibco Invitrogen Corp., Life Technologies 
Ltd. Paisley, Scotland 
C 
Hank’s balanced salt 
solution (HBSS) 
Gibco Invitrogen Corp., Life Technologies 
Ltd. Paisley, Scotland 
C 
HEPES solution (10mM) Gibco Invitrogen Corp., Life Technologies 
Ltd. Paisley, Scotland 
C 
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4.2  Instruments and methods 
 
The methods were flow injection (FIA) and liquid chromatography (LC) analysis using ultra violet 
(UV) or mass spectrometric (MS) detection. The instruments are listed in Table 6. The methods 
used are briefly described here with Tables 7-10. More detailed descriptions of the instrumental 
methods can be found in the original publications (A-C). 
 
Table 6. List of the instruments used for flow injection analysis (FIA), liquid chromatography (LC), 
ultra violet (UV) and mass spectrometric (MS) detection. 
 
Method Instrument Manufacturer Publication 
FIA Micro syringe pump Harvard Apparatus, USA A 
Rheodyne 7725 manual injector Cotati, Ca, USA A 
LC Liquid chromatograph, HP/Agilent 
1100 series 
Hewlett-Packard GmbH, 
Waldbronn, Germany 
B, C 
UV Ultraviolet detector, HP/Agilent Hewlett-Packard GmbH, 
Waldbronn, Germany 
B 
MS Sciex API300, mass spectrometer Sciex, Toronto, Canada A, B 
Sciex API3000, mass spectrometer Sciex, Toronto, Canada C 
ESI (pneumatically assisted 
electrospray) ionisation probe 
Sciex, Toronto, Canada A, C 
APCI (atmospheric pressure chemical 
ionisation) probe 
Sciex, Toronto, Canada B 
 
 
 
4.2.1 Nitrophenoxy benzoate study 
 
FIA-MS 
 
A sample of concentration 48 - 61 nmol/mL was introduced using FIA with a flow rate of 5 µl/min 
(Table 7). Higher orifice voltages (50-120 V) were used in the fragment ion MS/MS experiments in 
order to examine fragmentation pathways. The scan range was m/z 170-500 (3.1 sec/scan, dwell 
time 1.0 ms) for the mass spectrum and m/z 30-500 (3.1 sec/scan, dwell time 0.65 ms) for the 
product ion scan. The spectra were recorded by accumulating 10 spectra. 
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Table 7. Experimental parameters for flow injection analysis and mass spectrometry (FIA-MS) in 
nitrophenoxy benzoate study, article A. 
 
FIA-MS 
Sample introduction: Sample concentration 48 - 61 nmol/mL 
 Flow rate  5µl/min 
 Sample loop 10 µl 
 Solvent water: methanol (50:50), pH 11.6, adjusted by 
ammonium hydroxide 
Mass spectrometric parameter: Capillary voltage 5000 V 
 Orifice voltage 30 V, 
(50-120 V in high orifice voltage studies) 
 Collision energy 25 V 
 Nebulisen gas: Synthetic air (80% N2, 20% O2) 
 Curtain and Collision gas: Nitrogen 
 
4.2.2  IAM study  
 
UV and MS 
 
The ultraviolet (UV) detection method used the individual wavelength λmax presented in Tables 8 
and 9. Mass spectra of the analytes were recorded by directly injecting 100 µl (100 µM) of the 
individual compound solutions into the mass spectrometer from the liquid chromatography 
equipment. The mass spectrum was measured in the range m/z 150–550 (0.4 s/scan). Selected ion 
chromatograms in the experiments determining log kIAM values were performed by monitoring the 
intensities of protonated or deprotonated molecules of the analytes (Table 8). The final LC-UV or 
MS methods are summarised in Table 9. 
 
Table 8. Ultraviolet detection wavelength λmax and protonated (positive) or deprotonated (negative) 
ions in the mass spectrum of the compounds in the immobilised artificial membrane (IAM) 
chromatography study.  
 
 Compound UV λmax  Positive or negative ions in 
mass spectrum 
I Ibuprofen 220 nm 205 m/z (neg) 
II Indomethacin 275 nm 356 m/z (neg)  
III Ketoprofen 260 nm 253 m/z (neg) 
IV Midazolam 215 nm 326 m/z (pos) 
V Phenobarbital 235 nm 231 m/z (neg) 
VI Procaine 230 nm 237 m/z (pos) 
VII Propranolol 288 nm 260 m/z (pos) 
VIII Thioridazine 262 nm 371 m/z (pos) 
IX Timolol 295 nm 317 m/z (pos) 
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Table 9. Experimental parameters for immobilised artificial membrane (IAM) chromatography 
using ultraviolet or mass spectrometry detection in publication B. 
 
IAM UV or MS 
Chromatographic conditions: IAM.PC.DD2, 30 x 4.6 mm, (12 µm), Regis Technologies 
Inc., Morton Grove, IL, USA 
 Column temperature 30 °C 
 Flow rate 1 ml/min 
Ultraviolet detection: UV detection wavelength was individual compound (λmax)  
Mass spectrometric parameter: Mass spectrum recording 
 Dwell time: 0.1 ms 
 Charge needle current 3 µA 
 Probe temperature: 450 ºC 
 Orifice voltage: 15 V 
 Collision energy: 25 V 
 Nebulizer gas: Synthetic air (80% N2, 20% O2) 
 Curtain gas: Nitrogen 
 
 
LC: Two different buffers 
 
Two different buffers were used in IAM using an ultraviolet detector: 
a) 10 mM phosphate buffer with 0.2 g/l of potassium chloride and 8 g/l of sodium 
chloride and pH adjusted to 7.4 with phosphoric acid, and 
b) 10 mM ammonium acetate buffer with pH adjusted to 7.4 with ammonium 
hydroxide. 
All mass spectrometric IAM experiments were performed with 10 mM ammonium acetate buffer 
(pH 7.4). 
 
 
LC: Isocratic and gradient elution 
 
Isocratic experiments were performed without acetonitrile and with four different amounts of 
acetonitrile (10, 20, 30 and 35%) in the mobile phase. Acetonitrile was used for the elution of 
lipophilic compounds (indomethacin, midazolam, propranolol and thioridazine), which require an 
organic modifier if they are to be eluted within a reasonable time (30 min). Sample solutions for 
these experiments were prepared in 10% acetonitrile and 90% aqueous buffer with pH 7.4 and 
contained one analyte each (concentration 0.5 or 1 mM).  
 
A fast gradient was also used in the mass spectrometric study. The gradient program was identical 
to that described by Valko et al. (Valko, K. et al., 2000), that is: 0–1.5 min, 0% acetonitrile; 1.5–10.5 
min, 0–100% acetonitrile; 10.5–11.5 min, 100% acetonitrile; 11.5–12.0 min, 100–0% acetonitrile; 
12–20 min, 0% acetonitrile. The mixture of all the analytes (concentration of each analyte 100 µM) 
to be analysed in the IAM–APCI/MS experiments was prepared in 10% acetonitrile and 90% 
ammonium acetate buffer (pH 7.4). 
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Calculation of the retention factor 
 
Retention factors, k, for the five different isocratic mobile phase compositions (0, 10, 20, 30 and 
35% acetonitrile) were calculated according to the equation: 
 
k = (tr - t0)/t0. 
 
The t0 value (void time of the column) was measured by injection of sodium nitrite. The log kIAM 
values (log kw, theoretically corresponds to 0% acetonitrile) of the lipophilic compounds 
(indomethacin, midazolam, propranolol and thioridazine) were obtained from the linear plots of log 
k (y) vs. per cent of acetonitrile (x) by extrapolating to 0% acetonitrile. 
 
 
 
4.2.3 Caco-2 study 
 
 
Study samples 
 
The Caco-2 cells (ATCC) were cultured according to Andersberg and co-workers (Andersberg, E.K. 
et al., 1992) on polycarbonate filters of 0.4 µm pore size on 12-well plates (Corning Costar Corp., 
Cambridge, MA) at a seeding density of 75 000 cell/cm2. Cells were used in experiments between 
passages 29-30. Apical-to-basolateral (AP-BL) and basolateral-to-apical (BL-AP) transport of the 
studied drugs was followed over 120 minutes (15 min intervals). The pH of the apical transport 
medium (HBSS) was 5.5 and that of the basolateral medium was 7.4. 
 
 
LC-MS/MS 
 
A standard stock mixture containing 0.1 mg/ml of each study compound was diluted to an 
appropriate concentration with Hank’s balanced salt solution (HBSS) at pH 5.5 or 7.4. Caco-2 
analysis was performed with a liquid chromatography mass spectrometry system using 
pneumatically assisted electrospray ionisation (ESI). The liquid chromatographic set-up consisted 
of a binary pump, a column switching system and an autosampler (Table 10). The gradient program 
was 0.1 min–1.5 min, 10% acetonitrile; 1.5–6.5 min, 10–100% acetonitrile; 6.5–10 min, 100% 
acetonitrile; 10.0–11.0 min, 100–10% acetonitrile; 11–20 min, 10% acetonitrile. The eluent was 
introduced to waste for 1.5 min, after which the flow was directed by column switching to mass 
spectrometry. 
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Table 10. Experimental parameters for liquid chromatography and mass spectrometry for Caco-2 
samples, article C. 
 
LC-MS/MS in Caco-2 
Chromatographic conditions: Purospher STAR® C18 5.5 x 2mm (3 µm) -column, Merck, 
Darmstadt, Germany 
 Mobile phase: 15 mM ammonium acetate pH 3.5 : acetonitrile 
gradient 
 Column temperature: +30 °C. 
 The injection volume: 50 µl 
 Flow rate: 350 μl/min 
Column switching: Flow directed to waste: 0-1.5 min 
Sample filtration: Millex HV (0.45µm) polyvinylidene difluoride (PVDF) 
membrane filtration, Millipore Corp., Bedford, USA 
Sample dilution: With HBSS buffer (if needed) 
Splitter: Flow was split with the ratio 1:6 
Mass spectrometric 
parameter: 
Selected reaction monitoring (SRM) 
 Dwell time: 70 ms /each reaction 
 Ionspray voltage: 5500 V 
 Declustering/orifice potential, collisional energy and collision 
cell exit potential were individually optimised. 
 Nebulizing, curtain and collision gas: nitrogen 
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5. Results and discussion 
 
5.1 Nitrophenoxy benzoate study 
5.1.1 Fragmentation 
 
In routine analytical work, as Rivier and Pavlic with co-workers describe, standardised mass spectra 
libraries are a tool for the automatic characterisation of compounds (Rivier, L. et al., 2003, Pavlic, M. 
et al., 2006). With high resolution instruments, where standard compounds are absent, the accurate 
mass, nitrogen rules and mass detect filter rules assist (Tiller, P.R. et al., 2008). When the given 
instrument does not offer high mass accuracy, information on fragmentation is needed. Most of all, 
supporting information is required when the presence of the targeted compounds in combinatorial 
libraries is determined. 
 
The fragmentation of ten nitrophenoxy bentzoate compounds was investigated here. Several earlier 
studies have described positive (Benoit, F. and Holmes, J.L, 1970, Schwarz, H., 1974, Martens, J. et al., 
1975, Brophy, J.J. et al., 1979, Zitrin, S. and Yinon, J., 1976, Brown, P., 1970) and negative (Brown, C.L. 
and Weber, W.P., 1970, Bowie, J.H.,  1971, Bowie, J.H. and Nussey, B., 1972, Bowie, J.H. and Nussey, B, 
1974, Bowie, J.H. and Ho, A.C., 1974, Bowie, J.H. and Stapleton, B.J., 1975, Wilson, J.C. and Bowie, J.H., 
1975, Bowie, J.H., 1978, Bowie, J.H., 1974) ion spectra for different types of nitroaryl compounds. In 
these studies the fragmentation from M-. and M+. ions has been well characterised. However, the 
fragmentation of odd-electron molecular ions produced by electron impact differs from that of 
even-electron deprotonated molecules produced by ESI. 
 
The only ion in the negative ion ESI/MS spectra of alkyl 3-hydroxy-5-(4’-nitrophenyl) benzoates 
(A1-A5) and alkyl 3-hydroxy-5-(2’,4’-nitrophenyl) benzoates (B1-B5) is [M-H]-. The most 
probable deprotonation site is the phenolic hydroxy group. The product ion spectra of the [M-H]- 
ions of A1-A5 are alike, as are those of B1-B5. However, the spectra of the A series compounds 
differ significantly from those of the B series compounds (Tables 11 and 12). The fragmentation is 
clearly more abundant with compounds B1-B5 than with A1-A5, indicating the increased instability 
of the [M-H]- ion in compounds B1-B5 due to the presence of a second electron-withdrawing nitro 
substituent. The relative abundance of [M-H]- increases and the amount of fragmentation decreases 
with an increase in the length of the alkyl chain from methyl to pentyl: the energy transferred in the 
collision to the internal energy of the precursor ion decreases as the alkyl chain length increases, 
because the number of degrees of freedom in the molecule increases. 
 
The product ion spectra of [M-H]- of both A1-A5 and B1-B5 show an abundant nitrophenoxy ion, 
at m/z 138 and m/z 183, respectively. This is formed by the loss of 3-hydroxybenzoate (Schemes 1 
and 2). The extensive charge delocalization and stabilisation explain the high abundance. The 
relative abundance of the ion is significantly decreased with an increasing length of the alkyl chain, 
since the internal energy is distributed over a larger number of bonds and less energy is focused on 
the ether bond. 
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Table 11. Product ion spectra of [M-H]- of alkyl 3-hydroxy-5-(4’-nitrophenoxy)benzoates A1-A5 
 
 Compounds 
Ion, m/z (rel. abund. %) A1 A2 A3 A4 A5 
[M-H]- 288 (100) 302 (100) 316 (100) 330 (100) 344 (100) 
[M-H-CO]- 244 (37) 258 (20) 272 (20) 286 (13) 300 (9) 
[M-H-alkene]-  - 274 (15) 274 (14) 274 (6) 274 (6) 
[M-H-alkene-CO2]-  - 230 (11) 230 (9) 230 (6) 230 (6) 
[M-H-alkene-CO2-H2O]- 212 (8) 212 (4) 212 (4) 212 (2) 212 (0.4) 
[M-H-alkene-CO2-H2O-C2H2]- 185 (10) 186 (13) 186 (6) 186 (5) 186 (3) 
[[M-H-alkene-CO2-H2O-C4H2]- 162 (22) 162 (20) 162 (11) 162 (7) 162 (6) 
nitrophenoxy ion 138 (99) 138 (87) 138 (68) 138 (22) 138 (19) 
other ions 246 (8) 260 (8)  - 288 (5) 302 (2) 
 228 (5) 228 (4)  - 228 (3)  - 
 214 (5)  -  -  -  - 
  - 184 (4) 184 (4) 184 (3) 184 (1) 
 187.5 (4) 136 (5)  -  -  - 
 
 
 
Table 12. Product ion spectra of [M-H]- of alkyl 3-hydroxy-5-(2’,4’-dinitrophenoxy)benzoates B1-
B5 
 
 Compounds 
Ion, m/z (rel. abund. %) B1 B2 B3 B4 B5 
[M-H]- 333 (1) 347 (1) 361 (4) 375 (5) 389 (6) 
[M-H-HNO2]- 286 (71) 300 (65) 314 (100) 328 (100) 342 (100) 
[M-H-HNO2-alkene]-  - 272 (13) 272 (12) 272 (12) 272 (2) 
[M-H-HNO2-alkene-CO2]- 227 (10) 228 (33) 228 (32) 228 (20) 228 (18) 
[M-H-HNO2-alkene-CO2-NO]-  - 198 (3) 198 (3) 198 (1) 198 (2) 
dinitrophenoxy ion 183 (100) 183 (100) 183 (95) 183 (78) 183 (49) 
other ions 167 (7) 167 (5) 167 (5) 167 (4) 167 (4) 
  -  - 181 (4)  -  - 
 
 
 
The ion [M-H-HNO2]- is very intense in the product ion spectra of B1-B5, but does not appear in 
the spectra of A1-A5 (Tables 11 and 12). The hydrogen between the two strongly electron 
withdrawing nitro groups in B1-B5 is more acidic and is more likely eliminated along with NO2 
than is the hydrogen adjacent to the nitro group in compounds A1-A5. For the CID reactions of gas 
phase ions as energy selected systems, ab initio calculations may be carried out. Ab initio 
calculations performed with compound B2 at the 3-21G level of theory showed that the fragment 
ion [M-H-HNO2]- is 12.2 kcal/mol more stable when the nitro group is eliminated from the ortho 
than from the para position. 
 
In contrast to the dinitrophenoxy ion (m/z 183), the relative abundance of [M-H-HNO2]- in the 
spectra of B1-B5 increases with the length of the alkyl chain. The energy transferred in the collision 
activation to the precursor ion decreases as the length of the alkyl chain increases. This decrease in 
the internal energy has a stronger effect on the formation of nitrophenoxy ions than on the 
formation of [M-H-HNO2]- ions, and allows us to assume that more energy is required for the 
formation of nitrophenoxy ions than for the formation of [M-H-HNO2]- ions. Moreover, this energy 
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is evidently quite near the level of the internal energy transferred in the collision activation. It 
follows that when the alkyl chain length is increased, the relative abundance of [M-H-HNO2]- is 
increased at the expense of the relative abundance of the dinitrophenoxy ion. 
 
The ion m/z 274 in the spectra of A2-A5 is formed from [M-H]- by the cleavage of alkene from the 
ester group after McLafferty rearrangement. The ion m/z 272 in the spectra of B2-B5 is formed in 
the same way, but after cleavage of HNO2. Because the hydrogen transfer in McLafferty 
rearrangement requires a six-member ring transition state, the ions at m/z 274 and m/z 272 do not 
appear in the spectra of the methyl esters (A1 and B1). The intensities of the ions at m/z 272 and 
m/z 274 are slightly decreased with an increase in the length of the alkyl chain. The ions at m/z 230 
(A1-A5) and m/z 228 (B1-B5) are formed by the loss of CO2 from the ions at m/z 274 and m/z 272, 
respectively, and the ions at m/z 230 and m/z 228 are further fragmented by the loss of NO, 
producing very weak ions at m/z 200 (A1-A5) and m/z 198 (B1-B5), respectively. 
 
The unexpected ion [M-H-44]- formed by the loss of CO2 is seen in the spectra of A1-A5, but not in 
the spectra of B1-B5. Before the loss of CO2, the alkyl chain migrates from the ester moiety, 
evidently to the negatively charged phenolate oxygen. The semi-empirical calculations showed that 
the minimum of the electrostatic potential on the total electron density surface near the phenolate 
oxygen of the deprotonated molecule is -164.200 kcal/mol for A2 and -158.136 kcal/mol for B2. 
The lower value for A2 indicates that the nucleophilicity at the phenolate oxygen is significantly 
higher for A1-A5 than for B1-B5. This is because the electron withdrawing effect of two nitro 
groups is significantly greater than that of one nitro group. It follows that the higher nucleophilicity 
of the phenolate oxygen in compounds A1-A5 favours the migration of the alkyl chain to this 
moiety. The relative abundance of the ion [M-H-CO2]- decreases as the length of the alkyl chain 
increases, since the internal energy transferred in the collision activation also decreases. 
 
The ion m/z 186 in the spectra of A1-A5 is formed via two pathways, i.e. by the loss of 44 amu 
from m/z 230 and by the loss of 72 amu from m/z 258, shown by fragment ion tandem mass 
spectrometry. The MS/MS spectrum of m/z 186 reveals the loss of NO (m/z 156) and ion NO2
- (m/z 
46), indicating the presence of a nitro group. However, the structure of the ion m/z 186 cannot be 
reliably characterised with the available data. The ion m/z 162 is formed from m/z 258 by an 
unknown mechanism. 
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Scheme 1. The main CID fragmentation paths for [M-H]- of A2. 
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Scheme 2. The main CID fragmentation paths for [M-H]- of B2. 
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5.1.2 Combinatorial library screening 
 
The fragmentations of compounds A1-A5 are alike, as are those of compounds B1-B5. The 
similarity of fragmentation may often be the case with combinatorial libraries, since the basic 
structure of the compounds is similar. This feature can be exploited in the rapid assessment of the 
quality of the synthesis of combinatorial libraries, by employing precursor or neutral loss scans for 
compound identification. Figure 8 illustrates the precursor ion spectra of the nitrophenoxy ion of 
A1-A5 and B1-B5. The results rapidly tell whether the targeted compounds are present in the 
library. Only limited information is provided on the possible synthesis impurities. However, several 
improvements could be made to the presented method, such as chromatographic separation or the 
use of other detectors, if more information is needed. 
 
 
 
Figure 8. Precursor ion spectra of m/z 138 from nitrophenoxy benzoate compounds, A1-A5 (a), and 
m/z 183 from dinitrophenoxy benzoate compounds, B1-B5 (b). 
 43 
 
 
5.2  IAM study 
5.2.1 Retention factors of IAM data 
 
IAM data approximate the lipophilicity of the compound or the permeability through cell 
membranes. Permeability studies are used to assess blood-brain penetration (Reichel, A. and Begley, 
D., 1998) or for the assessment of oral absorption. In oral absorption studies, IAM data improve if 
combined with in silico parameters (Stewardt, B.H. and Chan, H.O., 1998, Yen, T.E. et al., 2005). 
Lipophilicity values also enable understanding of the behaviour of certain compounds in activity 
screening (Escuder-Gilabert, L. et al., 2000, Matysiak, J. et al., 2007) or improve the solute descriptors in 
QSAR analysis (Sprunger, L et al. 2007). The use of IAM results for estimating the volume of 
distribution was also encouraging (Hollosy, P. et al., 2006). Calculated IAM values using three 
analytical methods for nine drugs are presented in Table 13. 
 
Table13. Log kIAM values measured with no organic solvent or extrapolated to a zero amount of 
organic solvent. 10mM phosphate buffer pH 7.4 with a physiological salt concentration was used in 
the first IAM-UV method (I), and 10mM ammonium acetate buffer pH 7.4 in the second IAM-UV 
method (II) and in the IAM-APCI-MS method (III). 
 
Log kIAM IAM-UV 
(method I) 
IAM-UV 
(method II) 
IAM-APCI-MS 
(method III) 
Ibuprofen 1.20 1.07 1.17 
Indomethacin 2.16 2.10 1.91 
Ketoprofen 0.98 0.82 0.88 
Midazolam 2.49 2.44 2.49 
Phenobarbital 0.58 0.67 0.74 
Procaine 0.84 0.96 1.08 
Propranolol 2.16 2.36 2.23 
Thioridazine 3.88 3.49 3.43 
Timolol 0.95 1.24 1.32 
 
5.2.2 IAM columns 
 
Typical IAM columns contain phosphatidylcholine (PC) analogues chemically bonded to a 
propylamino-silica core (IAM-PC) (Yang, C.Y. et al., 1996). For example, IAM-PC-DD columns use 
phosphatidyl choline bound as single-chain, IAM-PC-DD2 as double chain and IAM-PC-MG uses a 
double chain of phosphatidyl choline with a glycerol linker (Barbato, F. et al., 2004, Ward, R.S. et al., 
2003). IAM-PC-DD and DD2 have end-capping of free propylamino residues with C10- and C3-
acyl groups and IAM-PC-MG with a glycerol linker is end-capped with methylglycolate (MG). In 
this study the IAM-PC-DD2 column was used. 
 
Comparison of IAM columns suggests that ionised compounds usually bind more strongly to IAM-
PC-MG columns than IAM-PC-DD. The IAM-PC-DD2 column with a double chain structure 
provides higher retention for neutrals compared to the earlier DD column. Generally, IAM-PC-DD 
and DD2 columns are more often used in drug membrane permeability studies, while IAM-PC-MG 
phases are more often used in protein purification (Barbato, F. et al., 2004, Ward, R.S. et al., 2003, Luo, 
 44 
H.B. et al., 2007). The chromatographic column immobilized with cholesterol has also been tested, 
but a correlation with physiological membrane penetration was not achieved (Al-Haj, M.A. et al., 
1998). 
 
The results of different laboratories should be easy to compare by using retention factors. 
Nevertheless, reported results may vary because of wide column selection. The repeatability of 
results over a longer time, however, was not investigated here. 
 
5.2.3 ESI suitable buffers 
 
The phosphate buffers normally used in IAM chromatography are inappropriate in atmospheric 
pressure chemical ionization (APCI) and electrospray ionisation (ESI), since they rapidly 
contaminate the ion source of the mass spectrometer. Ammonium acetate is a volatile buffer, widely 
used in liquid chromatography mass spectrometry, but rarely in IAM chromatography. Recently, 
Valko et al. (Valko, K. et al., 2000) used 50 mM ammonium acetate in IAM chromatography, but 
they did not directly compare their results with those obtained in phosphate buffered saline. Buffer 
concentrations higher than 10 mM may strongly suppress ionisation in ESI, leading to significantly 
decreased sensitivity. Although APCI tolerates much higher buffer concentrations than ESI, it is 
advantageous to use low buffer concentrations in APCI as well, to minimize chemical noise in the 
analysis. Accordingly, we tested the suitability of ammonium acetate as a buffer for IAM 
chromatography at a concentration of 10 mM. 
 
The first step in the method development was to show, with use of UV detection, that the log kIAM 
values measured with phosphate (method I) and ammonium acetate buffer (method II) are similar 
(Table 13). The measurements of the lipophilic compounds (indomethacin, midazolam, propranolol 
and thioridazine), which required an organic modifier for elution within a reasonable time (30 min), 
were made with 10, 20, 30 and 35% acetonitrile in the mobile phase. Extrapolation of the retention 
factor to a zero amount of organic modifier for lipophilic compounds was possible because, as was 
shown in earlier studies (Salminen, T. et al., 1997, Krause, E. et al., 1999, Valko, K. et al., 2000), the 
retention factors (log kIAM) change linearly. As can be seen from Table 13, the log kIAM values 
obtained with phosphate buffer and ammonium acetate buffer are very similar. Correlation analysis 
of the log kIAM values obtained with method I and II using different buffers gave an r2 of 0.970. The 
slight difference between the results may be explained as a salt effect. In the buffer of method I, the 
inorganic salts of potassium chloride and sodium chloride were included. The research group of 
Haroun (Haroun, M. et al., 2002) tested different salts against the retention of IAM chromatography 
and noticed some changes. They found that, in addition to lipophilic and hydrophobic effects, the 
properties of the amphiphilic solute with polar interfacial sites on the phospholipid monolayer may 
explain some of the differences. 
 
5.2.4  UV versus MS 
 
Positive and negative ion APCI mass spectra were recorded for the compounds in method 
development. The APCI spectra showed protonated molecules for indomethacin, ketoprofen, 
midazolam, procaine, propranolol, thioridazine and timolol, and deprotonated molecules for 
ibuprofen, indomethacin, ketoprofen and phenobarbital. Indomethacin was the only compound for 
which significant fragmentation was observed in positive and negative ion spectra. However, the 
deprotonated ion was intense enough for the single ion chromatography experiments performed in 
the log kIAM determinations. In accordance with the ionization efficiencies of the compounds, 
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midazolam, procaine, propranolol, thioridazine and timolol were monitored with [M+H]+ ions and 
ibuprofen, indomethacin, ketoprofen and phenobarbital with [M-H]- ions. 
 
The log kIAM values determined using 10mM ammonium acetate buffer and APCI ionization are 
reported in Table 13. Note that in IAM–APCI-MS, instead of the injection of each compound 
separately, the nine compounds were mixed together (100 µM each) and the mixture was directly 
injected onto the IAM column. The log kIAM values obtained by the n-in-one (III) method using 
IAM–APCI-MS correlate well with both the UV methods; correlation analysis gave an r2 value of 
0.991 with the UV ammonium acetate buffer method (II) and a value of 0.967 with the UV 
phosphate buffer method (I).  
5.2.5 Single versus n-in-one 
 
The disadvantage of the isocratic method is that several runs with increasing amounts of organic 
modifier must be made if the mixture includes lipophilic compounds. As demonstrated by Valko et 
al. (Valko, K. et al., 2000), the extra runs can be avoided by using gradient elution and reference 
compounds with known log kIAM values for calculation of the unknown log kIAM values. Figure 9 
illustrates selected ion chromatograms of the [M-H]- and [M+H]+ molecular ions obtained with the 
use of gradient elution (100% buffer to 100% acetonitrile in 10 min). All compounds eluted rapidly 
within 8 minutes. The ion chromatograms show good stability of the system; all compounds were 
clearly detected and the background ions did not disturb the detection. The elution order of the 
compounds in the gradient method was the same as the order of the log kIAM values calculated in 
isocratic runs, with the exception of midazolam and propranolol, which were in reversed order. The 
log kIAM values of midazolam and propranolol (2.49 and 2.23, Table 13) are in any event very 
similar. Our results demonstrate that gradient elution is suitable for lipophilicity ranking with the 
IAM–APCI-MS method. If log kIAM results are needed, the gradient run method should be 
calibrated with use of a homologous series appropriate for the studied compounds (Valko, K. et al., 
2000). Measurement in parallel artificial membrane permeation assay (PAMPA) screening methods 
often involves a well plate format and an automatic UV reader. Similarly, the n-in-one strategy for 
immobilised artificial membrane (IAM) chromatography with a multiplexed electrospray interface 
(MUX) could be evaluated. If the MUX technology includes four or eight channels of IAM columns 
for one MS detector, it increases the throughput. The computerised protocol to calculate retention 
factors should be easy to automate. 
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Figure 9. Extracted ion chromatograms of (a) [M+H]+ ions and (b) [M-H]- ions in immobilised 
artificial membrane chromatography (IAM) of nine compounds and gradient elution (100% buffer 
to 100% acetonitrile in 10 min). 
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5.3 Caco-2 study 
 
5.3.1 LC-MS/MS method 
 
The purpose of the Caco-2 study was to investigate cocktail dosing in the cell test. The role of the 
author was to develop a new analytical method based on LC-MS/MS. The Caco-2 tests are only 
discussed in literature survey, because the interpretation of the cell test results using n-in-one was 
performed by Leena Laitinen. 
 
The mass spectrometric separation allowed the use of a fast gradient in LC separation. All the 
compounds presented in Table 4, compounds C, were eluted within 8 minutes with good enough 
resolution (Figure 10).  A small particle column (3µm) was selected because of its good capability 
in chromatographic separation. The most polar compound, procaine, eluted first in 2.9 minutes 
before all the heterocyclic compounds. Because of the acidic mobile phase (pH 3.5), ketoprofen 
(pKa 4.8) was in its unionised form. Therefore, ketoprofen was the most lipophilic compound and 
also the last to elute, with a retention time of 7.5 minutes. 
 
To avoid instrument contamination and consequently poor reproducibility and decreased sensitivity, 
it was necessary to use column switching. Salts and other possible non-volatile materials in Caco-2 
samples were flushed to waste for 1.5 min, after which the eluent was directed to MS. Without 
column switching, the sensitivity decreased significantly due to contamination of the sampling 
orifice of the API source after 10-20 runs. The use of column switching also ensured that no 
suppression in the ionisation process was observed and good analytical reproducibility was 
achieved, including for co-eluting compounds.  
 
The ionisation efficiency in the positive ion mode for all the compounds studied was good and the 
spectra showed very abundant [M+H]+ ions with minimal fragmentation. However, the addition of 
formic acid was necessary to also achieve a good ionisation efficiency for acids. The protonated 
molecule was chosen for the precursor ion and two specific and intense product ions were chosen 
for each compound for multiple reaction monitoring. One product ion was used for quantitation and 
the other was a qualifier (Table 14). An external standard method was used in quantitative analysis 
instead of an internal standard method because of the heterogeneous characters of the compounds 
studied. 
 
The linearity of the method was studied between 50 and 2000 ng/ml (Table 14). Calibration graphs 
were constructed using spiked samples of at least six different concentrations in each series to cover 
the quantitative range. The calibration curves for all the compounds showed good linearity with 
correlation coefficients (r2) better than 0.990. The within-day precision of the method was evaluated 
with seven samples (250 ng/ml) and between-day precision with eight samples within 4 days. 
Relative standard deviations (RSD) for within-day and between-day experiments were below 10%, 
indicating acceptable precision of the analytical method. Procaine was an exception to the high 
within-day precision, with a value of 16%. The use of column switching allowed injection volumes 
of 50 µl that improved the limits of detection. Without column switching, injection volumes of 50 
µl rapidly contaminated the instrument. The sensitivity of the method was perhaps surprisingly 
good, because all too often the samples had to be diluted. If this had been known from the start, 
dilution might have been one of the sample pre-treatments itself. However, as carried out here, the 
method offered the promise of even more dilute Caco-2 cocktail analysis. In addition, it would be 
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better to continue the validation of the method. Selectivity was tested using blank samples and at 
the lower limit of quantitation (LLOQ) during sample analysis. In the future, accuracy should be 
validated with different calibration models and sample stability should be examined. 
 
The development of faster chromatographic separation could also be continued by using smaller 
diameter particles, but there is a risk of higher pack pressure. Different column materials, such as 
monolith phases, could also shorten the analysis time. As a follow-up study, with a similar set of 
compounds and a monolith column (Hakala, K. et al., 2003), the run was slightly shorter. Using the 
same ionisation as here, i.e. ESI (electrospray ionization), the chromatographic separation took 7 
minutes. A more important and substantial difference in the study of Hakala and co-workers was 
achieved by changing the ionisation to an APPI (atmospheric pressure photo-ionisation) detector, 
which resulted in an elution time of only 5.5 minutes. 
 
 
Table 14. The selected reaction monitored for quantitation (and qualifier ions) of ten compounds in 
Caco-2 sample; within-day and between-day (4 days) repeatability, LLOQ and linearity. 
 
 Repeatability, RSD LLOQ Linearity 
 Within day  % Between 4 days % (ng/ml) r2 
 (n=7) (n=8)   
Phenazone 189/104 7.5 8.5 10 0.994 
(Phenazone 189/147) 5.2 7.8 25 0.994 
Naproxen 231/170 5.0 14 25 0.990 
(Naproxen 231/185) 5.7 12 25 0.990 
Ketoprofen 255/105 4.9 4.7 5 0.994 
(Ketoprofen 255/209) 4.4 7.1 5 0.990 
Propranolol 260/116 3.1 3.1 5 0.996 
(Propranolol 260/183) 3.7 7.1 5 0.994 
Procaine 237/100 16 24 50 0.990 
(Procaine 237/120) 20 19 25 0.990 
Timolol 317/244 4.0 6.0 25 0.992 
(Timolol 317/261) 5.2 5.4 25 0.994 
Midazolam 326/291 6.8 9.1 10 0.994 
Hydroxyzine 375/201 7.0 8.8 10 0.990 
Buspirone 386/122 5.8 12 5 0.992 
(Buspirone 386/265) 2.6 8.2 25 0.990 
Verapamile 455/165 3.0 3.5 25 0.998 
(Verapamile 455/303) 2.6 6.4 25 0.994 
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Figure 10. Representative chromatograms for ten compounds in Caco-2 quantitation. 
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6. Conclusions 
 
Drug discovery has used liquid chromatography - mass spectrometric (LC-MS) methods because of 
their good sensitivity and selectivity. Combinatorial libraries need to be evaluated while new 
compounds are being rapidly synthesised and screened for their activity and other drug properties, 
such as lipophilicity and absorption. In first method described here, no chromatographic separation 
was carried out, but there was direct infusion to mass spectrometry. Ten nitrobentzoate compounds 
produced by combinatorial chemical synthesis were characterised, their fragmentation studied and 
the presence of the compounds determined in a combinatorial library.  
 
The CID fragmentation of ten nitrophenoxy benzoate compounds was studied by product and 
precursor ion scanning. Because of the serial homology in these chemicals, interesting structure-
fragmentation relationships were noticed. Two nitro group compounds increases fragmentation 
compared to one nitro group, whereas a longer alkyl chain stabilised the ion structure and less 
fragmentation was noticed from methyl to pentyl in both series. The most abundant product ions 
were nitrophenoxy ions. Common fragmentation made it possible to employ precursor ion scans to 
identify compounds in combinatorial mixtures. A precursor ion scan filters compounds from the 
matrix with better signal-to-noise ratios. 
 
Secondly, immobilized artificial membrane (IAM) chromatography was tested. This study was a 
method transfer and development study, where the traditional IAM chromatographic method using 
phosphate buffer and ultraviolet detection (UV) was changed to ammonium acetate buffer and mass 
spectrometric (MS) detection. Mass spectrometric detection scanned the mass spectrum separately 
in positive and negative modes, and the chromatographic retention of compounds was analysed 
using extract ion chromatograms. When changing detectors and buffers and including n-in-one in 
the method, the results showed good correlation. We demonstrated that the log kIAM values 
produced using ammonium acetate buffer are as reliable as those produced in phosphate buffer. 
Moreover, we also showed that analysis with MS gives as good results as with UV. Finally, the 
results demonstrated that mass spectrometric detection with gradient elution can provide a rapid and 
convenient n-in-one method for ranking the lipophilic properties of small organic drugs, including 
both acidic and basic compounds. 
 
The last study was set up in collaboration between research groups in pharmaceutical technology 
and pharmaceutical chemistry at the University of Helsinki. There was interest in determining 
whether drug-drug interaction occurred in the Caco-2 absorption cocktails. The analytical work 
aimed to develop a liquid chromatography mass spectrometric method for Caco-2 cocktail samples. 
All ten compounds required some chromatographic separation and mass spectrometric detection, 
using selective reaction monitoring, for quantitative analysis. 
 
The LC-MS/MS method offered ideal sensitivity, selectivity and sample capacity, especially for low 
sample concentrations and n-in-one cocktails. The absorption of ten chemically and physiologically 
different compounds was screened using both single and n-in-one approaches. The analysis was 
speeded up using the n-in-one cocktail, but the development of the method was also boosted by 
making it for several compounds at once. 
 
These three studies used mass spectrometry for compound identification, method transfer and 
quantitation in the area of mixture analysis. The selectivity of the mass spectrometric method is 
appreciated when analysing combinatorial synthesis, where possible side reactions of the synthesis 
could disturb the identification. Lipophilicity can rapidly be measured with multiple analytes at 
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once using immobilized artificial membrane (IAM) chromatography. With other in vitro or in silico 
methods, IAM chromatography has promising capabilities to estimate drug properties such as the 
volume of distribution and intestinal absorption or blood-brain penetration. In cocktail dosing 
studies, the concentrations are recommended to be kept at a minimum because of the risk of 
compound interactions. In the analysis of Caco-2 sample mixtures, especially with small 
concentrations, sensitive methods such as mass spectrometry are required. Different mass 
spectrometric scanning modes for the triple quadrupole instrument were used in each method. Early 
drug discovery with n-in-one is area where mass spectrometric analysis, its possibilities and proper 
use, is especially important. Past failures, such as unexpected compound interactions, have 
generally discouraged research into n-in-one. However, more information is needed, especially if 
the suitability of n-in-one is method-dependent. 
 52 
 
7. References 
 
 
Al-Haj, M.A.; Haber, P.; Kaliszan, R.; Buszewski, B.; Jezierska, M.; Chilmonzyk, Z., Mechanism of 
separation on cholesterol silica stationary phase for high-performance liquid chromatography as revealed by 
analysis of quantitative structure-retention relationships, J. Pharm. Biomed. Anal., 1998, 18, 721-728 
 
Allen, M.C.; Shah T.S.; Day, W.W., Rapid determination of oral pharmacokinetics and plasma free fraction 
using cocktail approaches: Methods and Application, Pharmaceutical Research, 1998, 15 (1), 93-97 
 
Anderberg, E.K.; Nyström, C.; Artursson, P., Epithelial transport of drugs in cell culture, VII, J. Pharm. Sci. 
1992, 81: 43-48, 879-887  
 
Armentrout, P.B.; Baer, T., Gas-Phase Ion dynamics and chemistry, J. Phys. Chem, 1996, 100, 12866-12877 
 
Artursson, P.; Palm, K.; Luthman, K., Caco-2 monolayer in experimental and theoretical predictions of drug 
transport, Advanced Drug Delivery Reviews, 2001, 46, 27-43 
 
Atherton, J.P.; Van Noord, T.J.; Kuo, B.-S., Sample pooling to enhance throughput of brain penetration 
study, J. Pharm. Biomed. Anal., 1999, 20, 39-47 
 
Balimane, P.V.; Han, Y-H.; Chong, S., Current industrial practices of assessing permeability and P-
glycoprotein interaction, The APPS Journal 2006, 8 (1), article 1: E1-E13 
 
Barbato, F.; di Martino, G.; Grumetto, L.; La Roonda, M.I., Prediction of drug-membrane interactions by 
IAM-HPLC: effects of different phospholipid stationary phases on the partition of bases, Eur. J. Pharm. Sci. 
2004,  22, 261-269 
 
Bedersford, A.P.; Selick, H.E.; Tarbit, M.H., The emerging importance of predictive ADME simulation in 
drug discovery, Drug Discov. Today, 2002, 7 (2), 109-116 
 
Benoit, F.; Holmes, J.L., Ortho effects-I: Fragmentation mechanisms in some ortho-substituted nitroarenes, 
Org. Mass Spectrom. 1970, 3, 993-1007 
 
Bergström, C.; Strafford, M.; Lazorove L.; Avdeef, A.; Luthman, K.; Artursson, P., Absorption classification 
of oral drug based on molecular surface properties, J. Med. Chem. 2003, 46, 558-570 
 
Berman, J.; Halm, K.; Adkison, K.; Shaffer, J., Simultaneous pharmacokinetic screening of a mixture of 
compounds in the dog using API LC/MS/MS analysis for increased throughput. J. Med. Chem., 1997, 40, 
827-829 
 
Bird, C.W.; Latif, M., A new synthesis of 3H-phenoxazin-3-ones, Tetrahedron 1980, 36, 529-533 
 
Bowie, J.H., Electron Impact studies. LXXXII: Negative ion mass spectrometry of functional groups. 
Collision induced spectra of the carboxyl group, Org Mass Spectrom. 1974, 9, 304-309 
 
Bowie, J.H.; Blumenthal, T.; White, P.Y., Electron Impact studies. CXXI: Release of kinetic energy during 
negative-ion fragmentations. The loss of NO. from substituted nitrobenzene molecular anions, Aust. J. 
Chem. 1978, 31, 573-577 
 
 53 
Bowie, J.H., Electron impact studies-LX: Negative-ion mass spectrometry of functional groups skeletal-
rearrangements in aryl nitro compounds, Org. Mass Spectrom. 1971, 5, 945-951 
 
Bowie, J.H.; Ho, A.C., Electron impact studies-LXXXVII: Ortho effects in the negative ion mass spectra of 
salicylates and anthranilates, Org. Mass Spectrom. 1974, 9, 1006-1016 
 
Bowie, J.H.; Nussey, B., Electron impact studies-LXXXIV: Substituent effects in the negative ion mass 
spectra of aryl esters, Org. Mass Spectro. 1974, 9, 310-320 
 
Bowie, J.H.; Nussey, B., Electron impact studies-LXX: Substituent effects in the negative-Ion spectra of 
nitroaryl esters, Org Mass Spectrom. 1972, 6, 429-442 
 
Bowie, J.H.; Stapleton, B.J., Electron impact studies. XCVI: Negative ion mass spectra of naturally 
occurring compounds, nitrophenyl esters derived from long-chain acids and alcohols, Aust. J. Chem. 1975, 
28, 1011-1015 
 
Brophy, J.J.;  Diakiw, V.; Goldsack, R.J.; Nelson, D.; Shannon, J.S., Anomalous ions in the chemical 
ionization mass spectra of aromatic nitro and nitroso compounds, Org. Mass Spectrom. 1979, 14, 201-203 
 
Brown, C.L.; Weber, W.P., Negative-ion mass spectrometry of polynitroaromatics, J. Am. Chem. Soc. 1970, 
92, 5775-5777 
 
Brown, P., Kinetic studies in mass spectrometry-IX: competing [M-NO2] and [M-NO] reactions in 
substituted nitrobenzenes. Approximate activation energies from ionization and appearance potentials, Org. 
Mass Spectrom. 1970, 4, 533-544 
 
Bu, H-Z.; Poglod, M.; Micetich R.G.; Khan, J.K., High-throughput caco-2 cell permeability screening by 
cassette dosing and sample pooling approaches using direct injection/on-line guard cartridge 
extraction/tandem mass spectrometry, Rapid Commun. Mass Spectrom. 2000, 14, 523-528 
 
Chackalamannil, S.; Desai, M., Editorial overview. Identifying quality leads - an important factor in reducing 
attrition of clinical candidates, Current Opinion in Drug Discovery & Development, 2007, 10 (4), 381-382 
 
Chakraborty, T.K.; Reddy, G.V., Studies directed toward the synthesis of glycopeptide antibiotic teicoplanin: 
first synthesis of the N-terminal 14-membered ring, J. Org Chem. 1992, 57, 5462-5469 
 
Cheng, Y.; Ho, E.; Subramanyam, B.; Tseng, J–L., Measurement of drug-protein binding by using 
immobilized human serum albumin liquid chromatography-mass spectrometry, J. Chromatography B 2004, 
809, 67-73 
 
Chu, I.; Nomeir, A.A., Utility of mass spectrometry for in vitro ADME assays, Current Drug Metabolism, 
2006, 7, 467-477 
 
Corti, G.; Maestrelli, F.; Cirri, M.; Furlanetto, S.; Mura, P., Development and evaluation of an in vitro 
method for prediction of human drug absorption I. Assessment of artificial membrane composition, Eur. J. 
Pharma. Sci. 2006, 27, 346-353 
 
Di, L.; Kerns; E. H., Profiling drug-like properties in discovery research, Current Opinion in Chemical 
Biology, 2003, 7, 402-408 
 
Dickins, M.; van de Waterdeemd, H., Simulation models for drug disposition and drug interactions, 
Drug Discovery Today: Biosilico, 2004, 2 (1), 38-45 
 
DiMasi J.A.., The value of improving the productivity of the drug development process, faster times and 
better decision, Pharmacoeconomics 2002: 20, Suppl. 3, 1-10 
 54 
 
Edwards, P.J.; Allart, B.; Andrews, M.J.; Clase, J. A.; Menet C., Expediting drug discovery: Recent 
advances in fast medicinal chemistry – optimization of hits and leads, Current opinion in Drug discovery & 
Development, 2006, 9 (4), 425-444 
 
Escuder-Gilabert, L.; Sagrado, S.; Villanueva-Camanas, R.M.; Medina-Hernandez, M.J., Development of 
predictive retention-activity relationship model of non-steroidal anti-inflammatory drugs by micellar liquid 
chromatography: Comparison with immobilized artificial membrane columns, J. Chromatography B, 2000, 
740, 59-70 
 
Fang, L.; Cournoyer, J.; Deemee, M.; Zhao, J.; Tokushige D.; Yan, B., High-throughput liquid 
chromatography ultraviolet/mass spectrometric analysis of combinatorial libraries using an eight-channel 
multiplexed electrospray time-of-flight mass spectrometer, Rapid Commun. Mass Spectrom. 2002, 16, 1440-
1447 
 
Feng, W.Y., Mass spectrometry in Drug Discovery: Current Review, Curr. Drug Discovery Tech. 2004, 1 
(4), 295-312 
 
Gallop, M.A.; Barrett, R.W.; Dower, W.J.; Fodor, S.; Gordon, E.M., Applications of combinatorial 
technologies to drug discovery 1. Background and peptide combinatorial libraries, J. Med. Chem. 1994, 37 
(9), 1233-1251 
 
Geoghegan, K.F.; Kelly, M.A., Biochemical applications of mass spectrometry in pharmaceutical drug 
discovery, Mass Spectrometry Reviews, 2005, 24, 347-366 
 
Ghose, A.K.; Viswanadhan, V.N.; Wendoloski, J.J., A knowledge-based approach in designing 
combinatorial of medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative 
characterization of known drug databases, J. Comb. Chem. 1999, 1, 55-68 
 
Corti, G.; Maestrelli, F.; Cirri, M.; Furlanetto, S.; Mura, P., Development and evaluation of an in vitro 
method for prediction of human drug absorption I. Assessment of artificial membrane composition, Eur. J. 
Pharma. Sci., 2006, 27, 346-353 
 
Guidance for Industry and FDA staff, Statistical guidance on reporting results from studies evaluating 
diagnostic tests, (FDA) March 2007 
 
Guidance for Industry, Bioanalytical method validation, (FDA) May 2001 
 
Guidance for Industry: Text on validation of analytical procedures, ICH-Q2A, (FDA) March 1995 
 
Guidance for Industry, Validation of analytical procedures: Definition and terminology, (FDA) July 1999 
 
Guidance for industry, Waiver of in vivo bioavailability and bioequivalence studies for immediate-release 
solid oral dosage forms based on a biopharmaceutics classification system, (FDA) August 2000, Attachment 
A 
 
Hakala, K.; Laitinen, L.; Kaukonen, A.M.; Hirvonen, J.; Kostiainen R.; Kotiaho, T., Development of 
LC/MS/MS method for cocktail dosed Caco-2 samples using atmospheric pressure photoionization and 
electrospray ionization, Anal. Chem. 2003, 75, 5969-5977 
 
Hakala, K.; Suchanova, B.; Luukkanen, L.; Ketola, R.; Finel M.; Kostiainen R., Rapid simultaneous 
determination of metabolic clearance of multiple compounds catalyzed in vitro by recombinant human UDP-
glucuronosyltransferases, Analytical Biochemistry 2005, 341, 105-112 
 
 55 
Han, H.K.; Sadagopan, N.; Reichard, G.A.; Yapa, U.; Zhu, T.; Hubbel, A.; Johnson, K.; Brodfuehrer, J., An 
efficient approach for the rapid assessment of oral rat exposures for new chemical entities in drug discovery, 
J. Pharm. Sci., 2006, 95, 1684-1692 
 
Haroun, M.; Dufresne, C.; Jourdan, E.; Ravel, A.; Grosset, C.; Villet, A.; Peyrin, E., Salt effects on the 
interaction of an amphiphilic model molecule with immobilized phosphatidylcholine monolayers, J. Chrom. 
A, 2002, 977, 185-192 
 
Hämäläinen, M.D.; Frostell-Karlsson, A., Predicting the intestinal absorption potential of hits and leads, 
Drug Discov. Today: Tech. 2004, 1 (4) 397-405 
 
He, K.; Qian, M.; Wong, H.; Bai, S.A.; He, B.; Brogdon, B.; Grace, J.E.; Xin, B.; Wu, J.; Ren, S.X.; Zeng, 
H.; Deng, Y.; Graden, D.M.; Olah, T.V.; Unger, S.E.; Luettgen, J.M.; Knabb, R.M.; Pinto, D.J.; Lam, P.Y.S., 
Duan, J.; Wexler, R.R.; Decicco, C.P.; Christ, D.D.; Grossman, S.J., N-in-1 Dosing Pharmacokinetics in 
Drug Discovery: Experience, Theoretical and Practical Considerations, J. Pharm. Sci., 2008, 97 (7), 2568-
2580 
 
Henchoz, Y.; Bard, B.; Guillarme, D.; Carrupt, P-A.; Veuthey, J-L.; Martel, S., Analytical tools for the 
physicohemical profiling of drug candidates to predict absorption/distribution, Anal. Bioanal. Chem., 2009, 
394, 707-729 
 
Hollosy, F.; Valko, K.; Hersey, A.; Nunhuch, S.; Keri, G.; Bevan, C., Estimation of volume of distribution in 
humans from high throughput HPLC-based measurements of human serum albumin binding and 
immobilized artificial membrane, J. Med. Chem. 2006, 49, 6958-6971 
 
Hop, C.E.; Wang, Z.; Chen, Q.; Kwei, G., Plasma-pooling methods to increase throughput for in vivo 
pharmacokinetic screening, J. Pharm. Sci. 1998, 87 (7), 901-903 
 
Hsieh, Y.; Bryant, M.S.; Brisson, J-M.; Ng, K.; Korfmacher, W.A., Direct cocktail analysis of drug 
discovery compounds in pooled plasma samples using liquid chromatography-tandem mass spectrometry, J. 
Chrom. B 2002, 767, 353-362 
 
Huang, R.; Qian, M.; Chen, S.; Lodenquai, P.; Zeng, H.; Wu, J.-T., Effective strategies for the development 
of specific, sensitive and rapid multiple-component assays for cassette dosing pharmacokinetic screening, 
Internat. J. Mass Spectrom. 2004, 238, 131-137 
 
ICH Harmonised Tripartite Guideline, Validation of analytical procedures: Text and methodology Q2 (R1), 
(ICH) October 1994 
 
Isbell, J., Changing requirements of purification as drug discovery programs evolve from hit discovery, J. 
Comb. Chem. 2008, 10, 150-157 
 
Jenkins, K.M.; Angeles, R.; Quintos, M.T.; Xu, R.; Kassel, D.B.; Rourick, R.A., Automated high throughput 
ADME assays for metabolic stability and cytochrome P450 inhibition profiling of combinatorial libraries, J. 
Pharm. Biomed. Anal. 2004, 34, 989-1004 
 
Kaliszan, R.; Nasal, A.; Turowski, M., Quantitative structure-retention relationships in the examination of 
the topography of the binding site of antihistamine drugs on α1-acid glycoprotein, J. Chromatography A, 
1996, 722, 25-32 
 
Kappe, O.C.; Dallinger, D., The impact of microwave synthesis on drug discovery, Nature Reviews, Drug 
Discovery, 2006, 5, 51-63   
 
Kennedy, J.P.; Williams, L.; Bridges, T.M.; Daniels, R.N.; Weaver, D.; Lindsley, C.W., Application of 
Combinatorial Chemistry science on modern Drug discovery, J.Comb. Chem. (published on Web 2008) 
 56 
 
Kostiainen, R.; Kauppila, T., Effect of eluent on the ionization process in liquid chromatography-mass 
spectrometry, J. Chromatogr. A, 2009, 1216, 685-699   
 
Koljonen, M.; Hakala, K.S.; Ahtola-Sätilä, T.; Laitinen, L.; Kostiainen, R.; Kotiaho, T.; Kaukonen, A.M.; 
Hirvonen, J., Evaluation of cocktail approach to standardise Caco-2 permeability experiments, Eur. J. 
Pharmaceutics and Biopharmaceutics 2006, 64, 379-387 
 
Krause, E.; Dathe, M.; Wieprecht, T.; Bienert, M., Noncovalent immobilized artificial membrane 
chromatography, an improved method for describing peptide-lipid bilayer interactions, J. Chromatography A 
1999, 849, 125-133 
 
Kuo, B.-S.; Van Noord, T.V.; Feng, M.R.; Wright, D.S., Sample pooling to expedite bioanalysis and 
pharmacokinetic research, 1998, 16, 837-846 
 
Lemke, T.; Willams, D., FOYE’s Principles of Medicinal Chemistry, by Wolters Kluwer Health/Lippincott 
Williams&Wilkins, 6th Edition, 2008 - Appendix A as a source of information 
 
Letot, E.; Koch, G.; Falchetto, R.; Bovermann, G.; Oberer L.; Roth, H.-J., Quality control in combinatorial 
chemistry: Determination of amounts and comparison of the “purity” of LC-MS-purified samples by NMR, 
LC-UV and CLND, J. Comb. Chem. 2005, 7, 364-371 
 
Li, A.C.; Gohdes, M.A.; Shou, W.Z., ”N-in-one” strategy for metabolite identification using a liquid 
chromatography/hybrid triple quadropole linear ion trap instruments sign multiple dependent product ion 
scans triggered with full mass scan, Rapid Commun. Mass Spectrom. 2007, 21, 1421-1430  
 
Liu, D.Q.; Xia, Y-Q.; Bakhtiar, R., Use of liquid chromatography/ion trap mass spectrometry/triple 
quadrupole mass spectrometry system for metabolite identification, Rapid Commun. Mass Spectrom., 2002, 
16, 1330-1336 
 
Lifshitz, C., Some recent aspects of unimolecular gas phase ion chemistry, Chem. Soc. Rev, 2001, 30, 186-
192 
 
Lipinski, C.A., et al., Experimental and computational approaches to estimate solubility and permeability in 
drug discovery and development settings. Advanced Drug Delivery Reviews, 1997, 23, 3-25 
 
Liu, H.; Sabus, C.; Carter, G.T.; Tischler M., Use of a linear gradient flow program for liquid 
chromatography mass spectrometry protein-binding assay. J. Chromatography A, 2002, 955, 237-243 
 
Loftsson, T.; Konradsdottir, F.; Masson, M., Development and evaluation of an artificial membrane for 
determination of drug availability, International Journal of Pharmaceutics, 2006, 326, 60-68 
 
Luo, H.B.; Zheng, C.; Cheng, Y.-K., Is phospholipids-saturated alkyl column a convenient replacement for 
immobilized –artificial-membrane? J. Chromatography A., 2007, 1176, 100-106 
 
Ma, S.; Subramanian, R., Detecting and characterizing reactive metabolites by liquid 
chromatography/tandem mass spectrometry, J. Mass Spectrom, 2006, 41, 1121-1139 
 
Manitpisitkul, P.; White, R.E., Whatever happened to cassette-dosing pharmacokinetics? Reviews, Drug 
Discov. Today, (Review) 2004, 9, 652-658 
 
Marchetti, N.; Cavazzini, A.; Gritti, F.; Guiochon, G., Gradient elution separation and peak capacity of 
columns packed with porous shell particles, J. Chromatography A. 2007 1163, 203-211 
 
 57 
Martens, J.; Praefcke, K.; Schwarz, H., Massenspektrometrische untersuchungen uber ortho-effekte und 
verwandte umlagerungen bei benzoe- und 2,2’-diphensäurederivaten, Liebigs Ann. Chem. 1975, 1, 62-74 
 
Masimirembwa, C.M.; Bredberg, U.; Andersson, T.B., Metabolic stability for drug discovery and 
development, Clin. Pharmacokinet., 2003, 42 (6), 2003 
 
Matysiak, J., Evaluation of electronic, lipophilic and membrane affinity effects on antiproliferative activity 
of 5-substituted-2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles against various human cancer cells, European 
Journal of Medicinal Chemistry, 2007, 42, 940-947 
 
McClellan, J.E.; Quarmby, S.T.; Yost, R.A., Parent and neutral loss monitoring on a quadrupole ion trap 
mass spectrometer: Screening of acylcarnitines in complex mixtures, Anal. Chem. 2002, 74, 5799-5806 
 
Mei, M.; Hsieh, Y.; Nardo, C.; Xu, X.; Wang, S.; Ng, K.; Korfmacher, W.A., Investigation of matrix effects 
in bioanalytical high-performance liquid chromatography/tandem mass spectrometric assays: application to 
drug discovery, Rapid. Commun. Mass Spectrom., 2003, 17, 97-103 
 
Mensch, J.; Noppe, M.; Adrianensen, J.; Melis, A.; Mackie, C.; Augustijns, P.; Brewster, M.E., Novel 
generic UPLC/MS/MS method for high throughput analysis applied to permeability assessment in early Drug 
Discovery, J. Chromatography B, 2007, 847, 182-187 
 
Nasal, A.; Wojdelko, A.; Baczek, T.; Kaliszan, R.; Cybulski, M.; Chilmonczyk, Z., Relationship between 
chromatographic behavior and affinity to 5-HT1A serotonin receptors of new buspirone analogues, Journal 
of Separation Science, 2002, 25, 273-279 
 
Newman, D. J.; Cragg, C.M.; Snader, K. M., Natural products as sources of new drugs over the period 1981-
2002, J. Nat. Prod. 2003, 66, 1022-1037 
 
Ohkawa, T.; Ishida, Y.; Kanaoka, E.; Takahashi, K.; Okabe, H.; Matsumoto, T.; Nakamoto, S.; Tamada, J.; 
Koike, M.; Yoshikawa, T., A new generic column switching system for quantitation in cassette dosing using 
LC/MS/MS, J. Pharm. Biom. Anal. 2003, 31, 1089-1099 
 
Palmgren, J.J.; Mönkkönen, J.; Jukkola, E.; Niva, S.; Auriola, S., Characterization of Caco-2 cell monolayer 
drug properties by cassette dosing using UV/fluorescence HPLC, Eur. J. Pharmaceutics and 
Biopharmaceutics 2004, 57 319-328 
 
Pavlic, M.; Libiseller, K.; Oberacher, H., Combined use of ESI-QqTOF-MS and ESI-QqTOF-MS/MS with 
mass-spectral library search for qualitative analysis of drugs, Anal. Bioanal. Chem. 2006, 386, 69-82 
 
Pedgraglio, S.; Rozio, M.G.; Misiano, P.; Reali, V.; Dondio, G.; Bigogno, C., New perspectives in bio-
analytical techniques for preclinical characterization of a drug candidate: UPLC-MS/MS in in vitro 
metabolism and pharmacokinetic studies, J. Pharm. Biomed. Anal., 2007, 44, 665-673 
 
Pehourcq, F.; Jarry, C.; Bannwarth, B., Potential of immobilized artificial membrane chromatography for 
lipophilicity determination of arylpropionic acid nonsteroidal anti-inflammatory drugs, J. Pharm. Biomed. 
Anal., 2003, 33, 137-144 
 
Peng, S.X.; Barbone, A.G.; Ritchie, D.M., High-throughput cytochrome P450 inhibition assays by ultrafast 
gradient liquid chromatography with tandem mass spectrometry using monolithic columns, Rapid Commun. 
Mass Spectrom. 2003, 17, 509-518 
 
Plumb, R.S.; Potts, W.B.; Rainville, P.D.; Alden, P.G.; Shave, D.H.; Baynham, G.; Mazzeo, J.R., Addressing 
the analytical throughput challenges in ADME screening using rapid ultra-performance liquid 
chromatography/tandem mass spectrometry methodologies, Rapid Commun. Mass Spectrom. 2008, 22, 
2139-2152 
 58 
 
Posner, B.A., High-throughput screening-driven lead discovery: Meeting the challenges of finding new 
therapeutics, Current Opinion in Drug Discovery & Development, 2005, 8 (4), 487-494 
 
Praveen, V.; Balimane, P.V, Han Y-H.; Chong, S., Current industrial practices of assessing permeability and 
P-glycoprotein interaction, The APPS Journal 2006, 8 (1), article 1: E1-E13 
 
Rajanikanth, M.; Gupta, R.C., LC fluorescence method for multiple synthetic compounds to rapidly create in 
vivo pharmacokinetic database utilizing N-in-One dosing, J. Pharm. Biomed. Anal. 2001, 26, 519-530 
 
The Regis Technologies presents their immobilized artificial membrane (IAM) chromatographic -products at 
the web-page; http://www.registech.com/InfoPages/IamInfo/IAMAbstracts.html 
 
Reichel, A.; Begley, D., Potential of immobilized artificial membranes for predicting drug penetration across 
the blood-brain barrier, Pharmaceutical Research 1998, 15 (8), 1270-1478 
 
Rivier, L., Criteria for the identification of compounds by liquid chromatography-mass spectrometry and 
liquid chromatography-multiple mass spectrometry in forensic toxicology and doping analysis, Analytica 
Chimica Acta, 2003, 492, 69-82 
 
Sadagopan, N.; Pabst, B.; Cohen, L., Evaluation of online extraction/mass spectrometry for in vivo cassette 
analysis, J. Chromatography B 2005, 820, 59-67 
 
Salminen, T.; Pulli, A.; Taskinen, J., Relationship between immobilised artificial membrane 
chromatographic retention and the brain penetration of structurally diverse drugs, J. Pharm. Biomed. Anal. 
1997, 15, 469-477 
 
Schuhmacher, J.; Zimmer, D.; Tesche, F.; Pickard, V., Matrix effects during analysis of plasma samples by 
electrospray and atmospheric pressure chemical ionization mass spectrometry: practical approaches to their 
elimination, Rapid. Commun. Mass Spectrom., 2003, 17, 1950-1957 
 
Schwarz, H., Elektronenstossinduzierte cyclisierung durch nachbargruppenwechselwirkung bei N-(O-
nitrobenzyl)-aminen, Org. Mass Specrom. 1974, 9, 826-830 
 
Shah, P.; Jogani, V.; Bagchi T.; Misra, A., Role of Caco-2 cell monolayers in prediction of intestinal drug 
absorption, Biotechnol. Prog. (Review) 2006, 22,  186-198 
 
Shin, B.S.; Yoon, C.H.; Balthasar, J.P.; Choi, B.Y.; Hong, S.H.; Kim, H.J.; Lee, J.B.; Hwang, S.W.; Yoo, 
S.D., Prediction of drug bioavailability in humans using immobilized artificial membrane 
phosphatidylcholine column chromatography and in vitro hepatic metabolic clearance, Biomed. 
Chromatogr., 2009, 23, 764-769  
 
Shin, Y.G.; van Breemen, R., Analysis and screening of combinatorial libraries using mass spectrometry, 
Biopharm. Drug Disposit. 2001, 22, 353-372 
 
Singh, R.P.; Singh, S.K.; Gupta, R.C., A high throughput approach for simultaneous estimation of multiple 
synthetic trioxane derivatives using sample pooling for pharmacokinetic studies, J. Pharm. Biomed. Anal. 
2005, 37, 127-133 
 
Smalley, J.; Kadiyala, P.; Xin, B.; Balimane, P.; Olah, T., Development of an on-line extraction turbulent 
flow chromatography tandem mass spectrometry method for cassette analysis of Caco-2 cell based bi-
directional assay samples, J. Chromatography B, 2006, 830, 270-277 
 
Smith, N.F.; Raynaud, F.I.; Workman, P., The application of cassette dosing for pharmacokinetic screening 
in small molecule cancer drug discovery, Mol. Cancer Ther., 2007, 6 (2), 428-440 
 59 
 
Sprunger, L.; Blake-Taylor, B.H.; Wairegi, A.; Acree Jr. W.E.; Abraham, M.H., Characterization of the 
retention behaviour of organic and pharmaceutical drug molecules on an immobilized artificial membrane 
column with the Abraham model, J. Chromatography A, 2007, 1160, 235-245 
 
Stahl, M., Guba, W.; Kansy, M., Integrating molecular design resources within modern drug discovery 
research: the Roche experience, Drug Discov. Today, 2006, 11(7/8), 326-222 
 
Stewardt, B.H.; Chan, H.O., Use of immobilized artificial membrane chromatography for drug transport 
applications, J. Pharm. Sci., 1998, 87 (12), 1471-1478 
 
Sugano, K.; Nabuchi, Y.; Machida, Mi.; Aso, Y., Prediction of human intestinal permeability using artificial 
membrane permeability, Inter. J. Pharmaceutics, 2003, 257, 245-251 
 
Taylor, P.J., Matrix effects: The Achilles heel of quantitative high-performance liquid chromatography-
electrospray-tandem mass spectrometry, Clinical Biochemistry, 2005, 38, 328-334 
 
Thompson, T.N., Optimization of metabolic stability as a goal of modern drug design, Medicinal Research 
Reviews, 2001, 21 (5), 412-449 
 
Tiller, P.R.; Y, S.; Castro-Perez, J.; Fillgrove, K.L.; Baillie, T.A., High-throughput, accurate mass liquid 
chromatography/tandem mass spectrometry on a quadrupole time-of-flight system as a “first-line” approach 
for metabolite identification studies, Rapid Commun. Mass Spectrom. 2008, 22, 1053-1061 
 
Triolo, A.; Altamura, M; Cardinali, F.; Sisto, A.; Maggi, C.A., Mass spectrometry and combinatorial 
chemistry: a short outline, J. Mass Spectrom., 2001, 36, 1249-1259 
 
Turpeinen, M.; Uusitalo, J.; Jalonen, J.; Pelkonen, O., Multiple P450 substrates in a single run: rapid and 
comprehensive in vitro interaction assay, Eur. J. Pharma. Sci., 2005, 24, 123-132 
 
Unger, K.K.; Skudas, R.; Schulte, M.M., Particle packed columns and monolithic columns in high-
performance liquid chromatography-comparison and critical appraisal, J. Chromatography A., 2008, 1184, 
393-415 
 
Valko, K.; Du, C.M.; Bevan, C.D.; Reynolds, D.P.; Abraham, M.H., Rapid Gradient HPLC method for 
measuring drug interaction with immobilized artificial membrane: comparison with other lipophilicity 
measures, J. Pharm. Sci. 2000, 89 (8),1085- 1096 
 
Venkatesh, S.; Lipper, R. A., Role of the development scientist in compound lead selection and optimization, 
J. Pharm. Sci., 2000, 89 (2), 
 
Ward, R.S.; Davies, J.; Hodges, G.; Roberts, D.W., Applications of immobilised artificial membrane 
chromatography to quaternary alkyl ammonium sulfobetaines and comparison of chromatographic methods 
for estimating the octanol-water partition coefficient, J. Chromatography A, 2003, 1007, 67-75 
 
Watanabe, T.; Schulz, D.; Morisseau, C.; Hammock, B.D., High-throughput pharmacokinetic method: 
Cassette dosing in mice associated with minuscule serial bleedings and LC/MS/MS analysis, Analytica 
Chimica Acta, 2006, 559, 37-44 
 
Watson, J.T.; Sparkman, O.D., Introduction to mass spectrometry: Instrumentation, applications and 
strategies for data interpretation, Wiley, 4th ed., England, 2008 
 
White, R.E.; Manitpisitkul, P., Pharmacokinetic theory of cassette dosing in drug discovery screening, Drug 
Metab. Dispos. 2001, 29, 957-966 
 
 60 
Williams, D.H.; Fleming, I., Spectroscopic methods in organic chemistry, McGraw-Hill Book Company, 4th 
Edition, 1989 
 
Wilson, J.C.; Bowie, J.H., Electron impact studies. XCIX: Negative ion mass spectrometry of the o-NO2-
C6H4-X-C6H5 systems. Aryl hydrogen scrambling and proximity effects, Org. Mass Spectrom. 1975, 10, 
836-841 
 
Xu, X.; Zhang, J.; Zhang, L.; Liu, W.; Weisel, C.P., Selective detection of monohydroxy metabolites of 
polycyclic aromatic hydrocarbons in urine using liquid chromatography/triple quadrupole tandem mass 
spectrometry, Rapid Commun. Mass Spectrom. 2004, 18, 2299-2308 
 
Yang, C.Y.; Cai, S.J.; Liu, H.; Pidgeon, C., Immobilized artificial membranes – screens for drug membrane 
interaction, Advanced Drug Delivery Reviews, 1996, 23, 229-256 
 
Yates, N.; Wislocki, D.; Roberts, A.; Berk, S.; Klatt, T.; Shen, D.-M.; Willoughby, C.; Rosauer, K.; 
Chapman, K.; Griffin, P., Mass spectrometry screening of combinatorial mixtures, correlation of measured 
and predicted electrospray ionization spectra, Anal. Chem. 2001, 73, 2941-2951 
 
Yen, T.E.; Agatonovic-Kustrin, S.; Evans, A.M.; Nation, R.L.; Ryand, J., Prediction of drug absorption 
based on immobilized artificial membrane (IAM) chromatography separation and calculated molecular 
descriptors. J. Pharm. Biomed. Anal. 2005, 38, 472-478 
 
Yu, H.; Adedoyin, A., ADME-Tox in drug discovery: integration of experimental and computational 
technologies, Drug Disc. Today, 2003, 8 (18), 852-861 
 
Yurek, D.A.; Branch, D.L.; Kuo, M.-S., Development of a system to evaluate compound identity, purity and 
concentration in a single experiment and its application in quality assessment of combinatorial libraries and 
screening hits, J. Comb. Chem. 2002, 4, 138-148 
 
Zhang, B.; Li, X.; Yan, B., Advances in HPLC detection – towards universal detection, Anal. Bioanal. 
Chem. 2008, 390, 299-301 
 
Zhang, L.; Strong, J.M.; Qiu, W.; Lesko, L.J.; Huang, S-M., Scientific perspectives on drug transporters and 
their role in drug interactions, Molecular Pharmaceutics, 2006, 3 (1), 62-69 
 
Zhao, J.; Can P.W., An approach to the concept of resolution optimization through changes in the effective 
chromatographic selectivity, Anal. Chem. 1999, 71, 2623-2632 
 
Zhao, S.; Forman, D.; Wallace, N.; Smith, B.; Meyer, D.; Kazolias, D.; Gao, F.; Soglia, J.; Cole, M.; 
Nettleton, D., Simple strategies for reducing sample loads in in vitro metabolic stability high-throughput 
screening experiments: A comparison between traditional, Two-time-point and Pooled sample analyses, J. 
Pharm. Sci. 2005, 94 (1), 38-45 
 
Zitrin, S.; Yinon, J., Chemical ionization mass spectra of 2,4,6-trinitroaromatic compounds, Org. Mass 
Spectrom. 1976, 11, 388-393 
 
 
